Section 5
Sexually Transmitted Infections
Background Information
The incidence of Sexually Transmitted Infections (STIs) in Saskatchewan has been increasing over the past number of years. This may be due in part to the introduction of testing procedures that are easier to complete and less invasive. In Saskatchewan, the rates for chlamydia have been among the highest in Canada. Refer to http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/c_indp_e.html#c_prov for historical surveillance data collected by Public Health Agency of Canada (PHAC).

STIs are transmitted in the context of other social and health challenges; the risk of recurrent exposure and infection are likely unless these underlying issues are dealt with. A holistic assessment of clients assists in identifying these underlying issues and a multidisciplinary team approach is often necessary and should involve other partners such as physicians, addiction services and mental health as required. The regulations of The Health Information Protection Act must be adhered to when involving other partners in the management of individuals or when referring individuals to other agencies.

This section highlights some of the general and special considerations that should be kept in mind when conducting STI investigations. It also highlights key points and summarizes the Canadian Guidelines on Sexually Transmitted Infections which can be located at http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php.

Reporting Requirements
Index cases must be reported to the Ministry of Health. See Reporting Requirements in the General Information section of this manual for additional information and guidelines.

Partner Notification
The goal of partner notification is to assist individuals to inform their partners that they have been put at risk and to honor the partner’s right to make informed decisions regarding their health.

Partner notification allows for sexual partners, and other contacts exposed to an STI, to be identified, located, assessed, counseled, screened and treated. This process is important in disease surveillance and control as well as for reducing the risk of re-infection for the original case. Refer to Section 1 for a summary of roles of individuals infected with/exposed to communicable diseases for additional information.
Sexually Transmitted Infections

Introduction and General Considerations

Date Reviewed: July, 2010

Individuals may experience a variety of feelings when they are informed that they have an STI. These feelings may range from guilt, to anger, to embarrassment. A non-judgmental approach can make clients feel more comfortable. Reassuring clients of the confidential nature of STI reporting may facilitate open communication and improve the disclosure of partner/contact information.

- Details on the required timeframes for initiating and completing contact notifications are included within each disease section.

Barriers to Partner Notification

There are a number of barriers that may prevent disclosure of contact names by cases. The following highlight some barriers:

- The index case may fear physical or emotional abuse that may result from partner notification. If there is a threat to client safety, public health officials should be notified of this so that proper safety precautions are taken to protect the index case. Concerns regarding personal safety should be addressed and if notification is expected to result in abuse, the case should be discussed with the Medical Health Officer (MHO) before proceeding.
- The individual may fear losing a partner due to the STI diagnosis (blame/guilt). The health care provider should acknowledge this and discuss the asymptomatic nature of STIs and the benefits of asymptomatic partner(s) knowing that they may be infected.
- Anonymous partners – details regarding the partner’s appearance and the location of the encounter should be obtained to try to locate the partner (contact). The Internet is becoming a common venue to meet prospective partners. E-mail addresses and any websites and/or chat rooms used should be collected. Identities may not be revealed when meeting partners in this forum thereby making contact notification a greater challenge. Policies relating to the use of the Internet and e-mail for partner notification must be referred to.

Who Performs Partner Notification?

The client, health care provider, MHO or their designate may notify the partner. When the person with the STI chooses to notify his or her contacts, they must inform the contact of the exposure, explain their duty to get tested and take all reasonable measures to reduce the risk of exposing others.1

---

Sexually Transmitted Infections
Introduction and General Considerations

Date Reviewed: July, 2010

If the affected person does not wish to notify their contacts on their own, the physician or clinic nurse can complete the partner notification. If the health care provider is unable to do this within 14 days, it should be referred to Public Health to complete. Notification by the health care provider occurs confidentially with the consent of the infected person. Partners will be notified of the possibility of their exposure to an STI (without naming the index case) and their responsibility to get tested and to take all reasonable measures to reduce the risk of exposing others (e.g., condoms, period of abstinence, safer sex practices, etc.).

Methods of Control
A holistic approach in determining the causes of STIs will reveal that there are a number of social circumstances that influence individual behaviours. This is significant when trying to determine broad prevention strategies, but is also important when meeting with individuals (cases, contacts, other) to develop approaches that assist and support them in making personal choices that reduce or eliminate risks. The following link is an excellent resource to assist health care providers with the prevention, diagnosis and management of STIs: http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php.

Primary Prevention
Public health professionals are engaged in a variety of activities with individuals and groups where health promotion and primary prevention measures can be introduced. A holistic, client-centered approach should be used to determine the most appropriate approaches and interventions that would be beneficial to the individual client or group being worked with. The topics outlined below for the assessment of individual sexual health and risk behaviours can also be adapted for use in other health education settings.

The following are topics that should be assessed when discussing sexual health and risk behaviours with individual clients and when providing health education in other community settings:

- relationships;
- sexual risk behaviours (number of partners, etc.);
- STI history;
- reproductive health history;
- substance use;
- psychosocial history.
Sexually Transmitted Infections

Introduction and General Considerations

Date Reviewed: July, 2010

Section: 5-10
Page 4 of 13

The Attachment - Risk Assessment Questionnaire is a sample questionnaire that can assist in determining what tests/referrals/counseling would be appropriate.

The information collected from this assessment will assist in identifying measures to reduce risk of exposure to STIs. It may also identify circumstances that could have an impact on the general health of the individual, for example, addressing substance use and other psychosocial issues may have a greater impact on the health of the client.

In addition to the counseling provided during the risk assessment, the following topics should also be addressed with any client that is receiving follow-up for an STI. These also apply to the follow-up of their partner(s):

- serial monogamy;
- acceptance of sexuality;
- planning prevention;
- safer sex;
- proper use of condoms;
- contraceptive advice.

Clients should be given information that is easy-to-apply:

- Discuss limiting alcohol or drug intake prior to sexual activity, as they both decrease inhibitions and could affect decision-making and negotiation skills.
- Reinforce that it is not possible to assess the chances that a partner has an STI on the basis of knowing the partner’s sexual history; being in a close relationship with a partner; or being monogamous with a partner who has had previous sexual partners and who has not been tested.
- It is important to tell clients that routine testing is not done for all STIs (e.g., human papilloma virus [HPV], herpes simplex virus [HSV]), so even if they or their partner’s tests are all negative they may still have an asymptomatic STI.

Secondary Prevention

Active screening of risks for STIs assists in the identification of individuals who may be infected with an STI. Testing should be offered to clients based on the results of the risk assessment.
Sexually Transmitted Infections

Introduction and General Considerations

Date Reviewed: July, 2010

Refer to Attachment - Risk Assessment Questionnaire for a tool that is available to assist in client assessment. This tool provides a framework for assessments and investigations and should be adapted to suit the situation and individual while keeping in mind the benefits of a broad assessment and how this information can be used. Testing should be offered to clients based on the results of the risk assessment.

General Recommendations for Testing based on Results of the Risk Assessment

Since the risk of human immunodeficiency virus (HIV) increases when a client is infected with another STI (chlamydia, gonorrhea, syphilis, HSV), HIV pre-test counselling should occur and HIV testing should be offered. Refer to Blood and Body Fluid Pathogens (Section 6) for information on HIV and testing procedures.

Clients with ongoing risks for infection with STIs should routinely be tested for:
- chlamydia;
- gonorrhea;
- HIV;
- syphilis.

If other risk factors are present, screening should be recommended for hepatitis B and hepatitis C:
- Individuals with multiple sexual partners are eligible for publicly funded hepatitis B vaccine if they are non-immune and are not HBsAg positive.
- Hepatitis C positive clients are eligible for publicly funded hepatitis A and/or hepatitis B vaccines if they are non-immune to hepatitis A or hepatitis B.
- Individuals born after January 1, 1984 are eligible for publicly funded hepatitis B vaccine.

Referrals
Clients may benefit from referrals to supportive services depending on the circumstances of exposure. Suggested referrals include child and youth services (Teen Wellness Centres), mental health services, pregnancy counseling clinics or addiction services to name a few. Familiarity with the available regional services and community resources will assist in making appropriate referrals. Procedures of the Health Authority should be followed when making referrals. One aspect of this includes ensuring the confidentiality of the client’s health information is maintained in accordance with *The Health Information Protection Act* and *The Public Health Act*.

Special Considerations

**Children/Sexual Abuse**
Every province and territory has statutes in place that require the reporting of child abuse. In Saskatchewan, the duty to report situations where they believe a child is being abused falls under *The Child and Family Services Act*. This duty applies in spite of any claim of confidentiality. The offences covered in this Act are outlined in Section 81. This Act also defines a child in the need of protection. *The Emergency Protection for Victims of Child Sexual Abuse and Exploitation Act*, also defines abuse and the duties to report instances or suspicions of child sexual abuse. If reasonable cause to suspect child abuse exists, the health care provider must contact local child protection services and/or law enforcement agencies promptly. The offences of this Legislation are outlined in Section 24 of this Act. Other resources that outline child protection issues include the *Criminal Code* and the *Provincial Child Abuse Protocol 2006*.

**Initial Laboratory Work-up**
Note: It is important to notify the lab if the laboratory specimens being submitted are for a child abuse/sexual assault case, as the urine specimen must undergo a second PCR test if the first result is positive.

- Cultures for *N. gonorrhoeae* and *C. trachomatis* from specimens collected from any sites of penetration or attempted penetration. See [Attachment - Transport Media for Specific STIs](#).

---

Sexually Transmitted Infections

Introduction and General Considerations

Date Reviewed: July, 2010
Section: 5-10
Page 7 of 13

- Urine nucleic acid amplification tests (NAATs) (as a substitute for culture).

Management and Treatment
Considerations for prophylaxis:
- Offer presumptive prophylaxis for STIs and hepatitis B:
  - in situations where vaginal, oral or anal penetration has occurred, because many sexual assault victims do not return for follow-up visits;
  - when it is known that the assailant is infected with a specific STI;
  - when it is requested by the patient/parent/guardian;
  - when the patient has signs or symptoms of an STI.
- Post-exposure administration of HBIG and/or hepatitis B vaccine may prevent hepatitis B virus infection.
  - It should be noted that the efficacy of antibiotic prophylaxis has not been studied in sexual assault; prophylaxis should be as recommended for treatment of specific infections (see sections on specific infections for more information).

Pregnancy
If pregnancy is a possible result of the assault, the emergency contraceptive pill (ECP) should be considered. Treatment should be offered and taken as soon as possible, up to 72 hours after exposure (efficacy declines after this, but some benefit may be achieved up to 120 hours after exposure).
- ECP is available through a physician or directly through some pharmacies and STI clinics.
- Preferred: levonorgestrel 1.5 mg PO as a single dose (Plan B).
- Alternative: levonorgestrel 0.75 mg PO bid x 2 doses if a single dose (as noted above) is not likely to be tolerated.
For further information on emergency contraception visit the Society of Obstetricians and Gynecologists of Canada, Clinical Practice Guidelines at http://www.sogc.org/guidelines/index_e.asp#Contraception.

Other Management Issues
• If the client consents, appropriate referral(s) should be made as necessary (e.g., to sexual assault teams, local police/Royal Canadian Mounted Police, psychological support, local victim support organizations etc.).
• Advise the client of the need to practice safer sex or abstinence from sexual intercourse until infection has been ruled out and/or prophylaxis is complete.
• Offer tetanus toxoid if relevant (e.g., dirty wounds/abrasions sustained outdoors).

Follow-up
• Follow-up testing of STIs (i.e., syphilis) should be recommended as necessary.
• In circumstances in which transmission of syphilis, HIV, or hepatitis B is a concern but the disease status of the source is unknown and baseline tests are negative, repeat testing should be done at 6, 12 and 24 weeks (depending on the infection being tested for) after the last suspected sexual exposure. See also the introduction to Blood and Bodily Fluid Borne Pathogens.
• Review mental state and arrange appropriate referral to mental health services if necessary.

Refer to the following link for detailed information on Children and Sexual Abuse: http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/606sexassault-eng.pdf.

Travel
There has been an association between travel, sexual behavior and the risk of acquiring sexually transmitted infections (STIs). The risk of acquiring STIs is increased in travellers because travel affords freedom from the normal social constraints of daily life at home as well as increased time and opportunity for casual sex. Studies have shown that 5 to 50 percent of travellers engage in casual sex and that a third to over one half of travellers do not consistently use condoms. Associated risk factors include being male, younger age, travelling alone or with friends, being single, men who have sex with men (MSM), long duration of stay, travelling on business, and being a smoker or using alcohol or illicit drugs.
Sexually Transmitted Infections

Introduction and General Considerations

Date Reviewed: July, 2010

STI rates are particularly high in developing countries. The incidence of antibiotic resistance to STIs is increasing (e.g., gonococcal strains may be resistant to penicillins, tetracyclines, spectinomycin, and fluoroquinolones). Additional information can also be obtained by consulting the Saskatchewan International Travel Manual or by visiting: http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/609travel-voyag-eng.pdf.

Sex Trade Workers

Sex workers are female, male or transgendered adults or young people who receive money, shelter, drugs or goods in exchange for sexual services, either regularly or occasionally, and who may or may not consciously define those activities as income-generating. Since there are no reliable verbal or visual clues as to whether a client is involved in the sex trade or not, when appropriate, patients should be asked whether they ever receive money, shelter or goods in exchange for sexual services.

The following include some factors that make sex workers vulnerable to STIs, including HIV:

- lack of control (e.g., condom use, refusing clients);
- lifestyle risks, such as violence, substance use and mobility;
- stigmatization and marginalization;
- limited economic options;
- limited access to health, social and legal services;
- limited access to information about and the means of prevention;
- gender-related differences and inequalities;
- sexual abuse and exploitation, including trafficking and child prostitution;
- legislation and policies affecting the rights of sex workers;
- mental health problems;
- incarceration;
- lack of family and social support.

Clinicians and health care providers need to understand the specific circumstances for each client and develop an individualized risk-reduction plan for each client. Successful STI/HIV prevention focuses on the promotion of safer sexual behaviour including the availability of female and male condoms and their correct usage; improved negotiating
skills; and supportive policies and laws. Peer education, outreach work, accessible services, advocacy, community development, program coordination and sex worker involvement in risk reduction programming are all important prevention principles and strategies.

Hepatitis B vaccination should be made available free of charge to sex workers since they are at increased risk for infection. See the Saskatchewan Immunization Manual\(^5\) for details of publicly funded immunizations. For more information on sex trade workers, go to [http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/607sexworkers-eng.pdf](http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/607sexworkers-eng.pdf).

**Inmates and Offenders**

Inmates in correctional facilities in Canada, and around the world, bear a disproportionate burden of illness related to infectious disease compared to the general population. As a result, rates of sexually transmitted infections (STIs), hepatitis B (HBV), hepatitis C (HCV) and HIV/AIDS are significantly higher among prison inmates.

See the introduction to [Blood and Body Fluid Pathogens](http://www.ehealthsask.ca/services/manuals/Pages/SIM.aspx) for more information on inmates and harm reduction.

**Reporting and Partner Notification**

Reporting must occur from the correctional facility to the local Public Health office. Partner notification is a major component of STI follow-up but inmates may be reluctant to disclose information about contacts or behaviours that may be deemed inappropriate, illegal or be stigmatized. This highlights the importance of confidentiality and a non-coercive approach to partner-notification process. Inmates view Public Health as an outside agency and therefore may be more willing to disclose information about contacts to Public Health.

**Follow-up**

Inmates who continue to engage in higher risk behaviour should be encouraged to be screened regularly for STIs. Safer sex and harm reduction practices should be reinforced with these clients.

\(^5\) [http://www.ehealthsask.ca/services/manuals/Pages/SIM.aspx](http://www.ehealthsask.ca/services/manuals/Pages/SIM.aspx)
Sexually Transmitted Infections

Introduction and General Considerations

It is important for collaboration to occur between correctional services and local public health to ensure follow-up occurs with those who have been/will be released into the community. For more information, go to http://www.phac-aspc.gc.ca/sti-its/pdf/602offend-eng.pdf.

Immigrants and Refugees

Immigrants and refugees\(^6\) may come from countries with higher rates of STIs than Canada. STIs that are relatively uncommon in Saskatchewan may be common in these countries and there may also be higher rates of drug resistance with some of these STIs. There are a number of variables that health care workers must be sensitive to when working with these clients. These may include:

- language barriers;
- cultural norms;
- social norms;
- gender roles;
- religion;
- personal experiences from their country of origin may have been traumatic.

A culturally sensitive approach must be used when working with clients. Anonymity and confidentiality must be maintained when utilizing translation or other supportive services and should include the consent of the individual.

See the introduction to Blood and Body Fluid Pathogens for more information on immigrants and refugees or go to http://www.phac-aspc.gc.ca/sti-its/pdf/601immigrants-eng.pdf.

\(^6\) A legal immigrant is a person born outside of Canada who has been granted the right to live in Canada permanently by immigration authorities, whereas an illegal immigrant has not been granted such a right. A refugee is a person outside his/her country of nationality who is unable or unwilling to return because of persecution on account of race, religion, nationality, membership in a particular social group, and/or political opinion.
Substance Use/Abuse
The use of alcohol and illicit drugs is associated with risky sexual behaviour including: poor and inconsistent condom use; sex with multiple partners; early sexual debut; trading sex; buying sex; sex with known injection drug users; lower condom-use self-efficacy or perceived ability to use condoms; and lower HIV-related knowledge (Public Health Agency of Canada, 2008).

- Substance use has also been linked to elevated hepatitis C and STI transmission.
- Users of more stigmatized substances, such as injection drugs and crack, are at higher risk for STIs than users of less stigmatized drugs, such as marijuana.
- Youth who abuse substances are more likely to engage in risky sexual behaviour and continue these risky behaviours and drug use into adulthood.
- The use of recreational drugs among men who have sex with men (MSM) has risen in recent years and has been linked to increases in risky sexual behaviour and rising STI rates. Sildenafil citrate (Viagra), vardenafil (Levitra) or tadalafl (Cialis) can be used to counteract the erectile-dysfunction side effect of some of these illicit drugs, a practice that has been linked to multiple sex partners and STI acquisition.

When substance use/abuse is identified as a risk, it is important to provide counselling and make referrals to community resources as appropriate. For more information go to http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/608substance-eng.pdf.
References


Sexually Transmitted Infections

Chlamydia

Reviewed: January, 2012

Section: 5-20
Page 1 of 7

Notification Timeline:
From Lab/Practitioner to Public Health: Within 72 hours.
From Public Health to Saskatchewan Ministry of Health: Within 2 weeks.
Public Health Follow-up Timeline: Initiate within 72 hours.

Infectious Agent
Bacterial infection caused by Chlamydia trachomatis serovars D to K.

Case Definition (Public Health Agency of Canada, 2008)
Genital Infections:
Confirmed Case:
Laboratory evidence of infection in genitourinary specimens:
• detection of C. trachomatis by culture;
  OR
• detection of C. trachomatis nucleic acid;
  OR
• detection of C. trachomatis antigen.

Extra-genital Infections:
Confirmed Case:
Laboratory evidence of infection in rectum, conjunctiva, pharynx and other extra-genital sites:
• detection of C. trachomatis by culture;
  OR
• detection of C. trachomatis nucleic acid;
  OR
• detection of C. trachomatis antigen.

Perinatally Acquired Infections:
Confirmed Case:
Laboratory evidence of infection:
• detection and confirmation of C. trachomatis in nasopharyngeal or other respiratory tract specimens from an infant who developed pneumonia in the first 6 months of life:
  • isolation of C. trachomatis by culture;
    OR
Sexually Transmitted Infections

Chlamydia

Reviewed: January, 2012

- demonstration of *C. trachomatis* nucleic acid;
- demonstration of *C. trachomatis* antigen.

OR

- detection and confirmation of *C. trachomatis* in conjunctival specimens from an infant who developed conjunctivitis in the first month of life:
  - isolation of *C. trachomatis* by culture;
  - demonstration of *C. trachomatis* nucleic acid;
  - demonstration of *C. trachomatis* antigen.

Identification

Table 1. Symptoms and Signs

<table>
<thead>
<tr>
<th>Females</th>
<th>Males</th>
<th>Neonates and infants</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Most often asymptomatic</td>
<td>• Often asymptomatic</td>
<td>• Conjunctivitis in neonates</td>
</tr>
<tr>
<td>• Cervicitis</td>
<td>• Urethral discharge</td>
<td>• Pneumonia in infants &lt;6 months of age</td>
</tr>
<tr>
<td>• Vaginal discharge</td>
<td>• Urethritis</td>
<td></td>
</tr>
<tr>
<td>• Dysuria</td>
<td>• Urethral itch</td>
<td></td>
</tr>
<tr>
<td>• Lower abdominal pain</td>
<td>• Dysuria</td>
<td></td>
</tr>
<tr>
<td>• Abnormal vaginal bleeding</td>
<td>• Testicular pain</td>
<td></td>
</tr>
<tr>
<td>• Dyspareunia</td>
<td>• Conjunctivitis</td>
<td></td>
</tr>
<tr>
<td>• Conjunctivitis</td>
<td>• Proctitis (commonly</td>
<td></td>
</tr>
<tr>
<td>• Proctitis (commonly asymptomatic)</td>
<td>asymptomatic)</td>
<td></td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

Table 2. Major Sequelae

<table>
<thead>
<tr>
<th>Females</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Pelvic inflammatory disease</td>
<td>• Epididymo-orchitis</td>
</tr>
<tr>
<td>• Ectopic pregnancy</td>
<td>• Reiter syndrome</td>
</tr>
<tr>
<td>• Infertility</td>
<td></td>
</tr>
<tr>
<td>• Chronic pelvic pain</td>
<td></td>
</tr>
<tr>
<td>• Reiter syndrome</td>
<td></td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.
Sexually Transmitted Infections
Chlamydia

Reviewed: January, 2012

Incubation Period
At least one week, most commonly 2-3 weeks, can be as long as 6 weeks.

Reservoir
Humans.

Mode of Transmission
- Genital infection is transmitted sexually.
- Ocular infections are presumably caused by inoculation of the eye with infected genital secretions (self-inoculation), (Sowka, J., et al., 2000).
- Oculogenital infection is transmitted from genital tract of mother to her newborn infant.

Period of Communicability
Unknown, poorly defined.

Specimen Collection and Transport
Genital Infection:
- Urine for PCR in men and women. Initial 10 to 20 mL of the urine stream (not mid-stream).
- Serology is not useful for the diagnosis of acute genital chlamydial infections.
- Post-exposure testing with a nucleic acid amplification test (NAAT) can be done as soon as desired, since it is not necessary to wait for 48 hours after exposure to collect samples as in the case of cultures.

Extra-genital Infection:
- Culture is recommended for throat and rectal specimens, since NAATs have not been adequately evaluated on these specimens.

Perinatally Acquired Infections:
- *C. trachomatis* IgM serology is useful for diagnosing *C. trachomatis* pneumonia in infants less than 3 months of age.

For information on specimen sources and culture media refer to Attachment – Transport Media for Specific STIs.
Sexually Transmitted Infections

Chlamydia

Occurrence

- Common worldwide.
- Reported rate is highest in women age 15 to 24 years and in men age 20 to 29 years.
- Underdiagnosed due to majority of infected individuals being asymptomatic.
- Underscreening of high-risk males and females. Males often have infrequent health maintenance visits (Public Health Agency of Canada, 2010).
- Without treatment, infection persists for many months.
- Often a co-infection for those diagnosed with Neisseria gonorrhoeae.

Susceptibility

General.

- Risk factors include:
  - sexual contact with a chlamydia-infected person;
  - a new sexual partner or more than two sexual partners in the past year;
  - previous sexually transmitted infections (STIs);
  - vulnerable populations (for example injection drug users, incarcerated individuals, sex trade workers, street youth, aboriginal etc.).

Methods of Control

Preventive Measures

Refer to Introduction and General Considerations of STI section of manual for information that should be shared for education and high-risk groups/activities that should be considered.

Every newborn in a hospital receives preventative treatment for ophthalmia neonatorum with erythromycin ophthalmic prophylaxis or another therapeutic agent considered to be a suitable substitute.

Immunization

Currently no vaccine for C. trachomatis.

Control of Patient

Treatment for chlamydia is indicated for the following:

- a positive chlamydia test;
Sexually Transmitted Infections

Chlamydia

Reviewed: January, 2012

Section: 5-20
Page 5 of 7

- diagnosis of a syndrome compatible with a chlamydial infection, without waiting for the test results of *C. trachomatis*;
- diagnosis of chlamydial infection in a sexual partner;
- empirical co-treatment when a diagnosis of *N. gonorrhoeae* is made without waiting for test results of *C. trachomatis* due to the significant probability of coinfection (20-42%) and the possibility of false negative results.

Patients and contacts should abstain from unprotected intercourse until treatment of both partners is complete (i.e., 7 days after completion of a multiple-dose treatment or for 7 days after single-dose therapy).

**Treatment**

- Drug resistance is rare but may become an emerging issue.

**Referrals**

Consider additional testing for STI pathogens based on the risk assessment found in the Introduction and General Considerations of this section. Refer to supportive services as indicated (see Introduction and General Considerations).

**Control of Contacts**

To prevent reinfection, partners need to be assessed, tested, treated, and counselled. All partners who have had sexual contact with the index case within 90 days prior to symptom onset or date of diagnosis should be tested and treated. If there is no partner during this period, the last partner should be tested and treated. Neonates born to infected mothers must be tested for *C. trachomatis*.

**Follow-up**

Test of cure for *C. trachomatis* is not routinely indicated if a recommended treatment is taken AND symptoms and signs disappear AND there is no re-exposure to an untreated partner.
Sexually Transmitted Infections

Chlamydia

Test of cure should be performed 4 weeks following completion of treatment in the following circumstances:

- recommended treatment taken but signs and symptoms persist;
- where compliance is suboptimal;
- if an alternative treatment has been used;
- in all prepubertal children;
- in all pregnant women.

Repeat testing in all individuals is recommended 6 months post-treatment, as re-infection risk is high. Positive NAAT test results within 30 days of treatment should be considered a duplicate case unless re-infection is likely to have occurred.

If erythromycin or amoxicillin has been used for treatment of nursing mothers, a test of cure should be done 4 weeks following completion of treatment.
Sexually Transmitted Infections

Chlamydia

Reviewed: January, 2012

Section: 5-20

Page 7 of 7

References


Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015

Notification Timeline:

From Lab/Practitioner to Public Health: Within 72 hours.
From Public Health to Saskatchewan Health: Within 2 weeks.

Public Health Follow-up Timeline: Initiate within 72 hours.

Infectious Agent

Bacterial infection caused by *Neisseria gonorrhoeae*.

Case Definition (Public Health Agency of Canada, 2008)

**Genital Infections:**

**Confirmed Case:**
Laboratory confirmation of infection in genitourinary specimens:
- detection of *N. gonorrhoeae* by culture;
  OR
- detection of *N. gonorrhoeae* nucleic acid.

**Extra-genital infections:**

**Confirmed Case:**
Laboratory confirmation of infection from pharynx, rectum, joint, conjunctiva, blood and other extra-genital sites:
- detection of *N. gonorrhoeae* by culture;
  OR
- detection of *N. gonorrhoeae* nucleic acid.

**Perinatally Acquired Infections:**

**Confirmed Case:**
Laboratory confirmation of infection from a neonate in the first 4 weeks of life leading to the diagnosis of gonococcal conjunctivitis, scalp abscess, vaginitis, bacteremia, arthritis, meningitis or endocardiditis:
- detection of *N. gonorrhoeae* by culture;
  OR
- detection of *N. gonorrhoeae* nucleic acid.
# Sexually Transmitted Infections

## Gonococcal Infections

Date Reviewed: May, 2015  
Section: 5-30  
Page 2 of 9

### Identification

**Table 1. Manifestations**

<table>
<thead>
<tr>
<th>Neonates and infants</th>
<th>Children</th>
<th>Youths and adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Females</td>
</tr>
<tr>
<td>Ophthalmia</td>
<td>Urethritis</td>
<td>Cervicitis</td>
</tr>
<tr>
<td>Neonatal amniotic fluid infection</td>
<td>Vaginitis</td>
<td>Pelvic inflammatory disease</td>
</tr>
<tr>
<td>Disseminated gonococcal infection</td>
<td>Conjunctivitis</td>
<td>Urethritis</td>
</tr>
<tr>
<td></td>
<td>Pharyngeal infection</td>
<td>Perihepatitis</td>
</tr>
<tr>
<td></td>
<td>Proctitis</td>
<td>Bartholoniitis</td>
</tr>
</tbody>
</table>

*Infections of pharynx and rectum are often asymptomatic (Heymann, 2015)*  
Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

### Table 2. Symptoms of genital tract infection with N. gonorrhoeae

<table>
<thead>
<tr>
<th>Neonates</th>
<th>Females</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjonctivitis</td>
<td>Vaginal discharge</td>
<td>Urethral discharge</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Dysuria</td>
<td>Dysuria</td>
</tr>
<tr>
<td></td>
<td>Abnormal vaginal bleeding</td>
<td>Urethral itch</td>
</tr>
<tr>
<td></td>
<td>Lower abdominal pain</td>
<td>Testicular pain, swelling</td>
</tr>
<tr>
<td></td>
<td>Rectal pain and discharge if proctitis</td>
<td>or symptoms of epididymitis</td>
</tr>
<tr>
<td></td>
<td>Deep dyspareunia</td>
<td>Rectal pain and discharge if proctitis</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.  
**Notes:**  
- Many patients are asymptomatic or have symptoms not recognized to be due to *N. gonorrhoeae*.  
- Contacts are also likely to be asymptomatic.  
- Long-term carriage occurs.
Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015

Table 3. Major Sequelae

<table>
<thead>
<tr>
<th>Females</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic inflammatory disease (PID)</td>
<td>Epididymo-orchitis</td>
</tr>
<tr>
<td>Infertility</td>
<td>Reiter syndrome</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>Infertility (rare)</td>
</tr>
<tr>
<td>Chronic pelvic pain</td>
<td>Disseminated gonococcal infection</td>
</tr>
<tr>
<td>Reiter syndrome</td>
<td></td>
</tr>
<tr>
<td>Disseminated gonococcal infection</td>
<td></td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

Incubation Period
Usually 2-7 days.

Reservoir
Humans.

Mode of Transmission
Genital infections: contact with exudates from mucous membranes of infected people, typically as a result of sexual activity.
Perinatal infections: passage through birth canal.
Secondary gonococcal bacterial conjunctivitis may follow accidental inoculation by fingers (Sowka, J., et al., 2000).

Period of Communicability
Effective treatment ends communicability within hours. Without treatment, communicability may extend for months.

Specimen Collection and Transport
In response to increasing gonococcal antimicrobial resistance being observed in Canada and other parts of the world, enhanced public health monitoring of trends in antimicrobial resistance patterns is desirable. While nucleic acid amplification tests (NAAT) are non-invasive and have high sensitivity and specificity, culture of at least some patients is necessary to guide therapy and to provide adequate data for surveillance of antimicrobial resistance.
Whenever possible, cultures for *N. gonorrhoeae* should be done, especially in the following circumstances:

1. In men who have sex with men (MSM), cultures are recommended in symptomatic patients prior to treatment. NAAT should continue to be used for screening genital tract specimens (urine, cervix or urethra) from asymptomatic individuals. Due to increased sensitivity of NAAT over culture, both gonococcal culture and NAAT may be indicated.
2. Patients with a travel history during the potential period of exposure.
3. For all cases, test of cure with an appropriate sample for gonococcal culture is recommended for any of the following situations:
   a. All pharyngeal infections
   b. Persistent signs or symptoms post-treatment
   c. Cases treated using a regimen other than the preferred treatment
   d. Case who is linked to a drug resistant/treatment failure case and was treated with that same antibiotic.

**Genital infection:**
- NAAT should be performed on first void urine because of greater sensitivity than culture
- Culture and Gram stain are recommended for the following specimens:
  - urethra in young and adult males with or without meatal discharge;
  - cervix in young and adult females.
- Culture is recommended for the following specimens:
  - rectum in females and males who have sex with men (colonization can occur without anal intercourse);
  - vagina in prepubertal girls or women without cervix.

**Extra-genital infection:**
- Culture:
  - pharynx in those with a history of oral-genital contact;
  - conjunctiva for ocular infections.

**Disseminated infection:**
- genital testing as outlined above;
- blood culture;
- synovial fluid for culture and gram stain if arthritis;
Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015
Section: 5-30
Page 5 of 9

- Gram stain and culture of skin lesion.

Special considerations:
Cultures obtained less than 48 hours after exposure may be negative.
- Culture is especially important in the following cases:
  - sexual abuse of children (rectal, pharyngeal, vaginal);
  - sexual assault;
  - treatment failure;
  - evaluation of pelvic inflammatory disease (PID);
  - infection acquired overseas or in areas with recognized antimicrobial resistance.

NAAT should not be used for test of cure.
For information on specimen sources and culture media refer to Attachment - Transport Media for Specific STIs.

Occurrence
- Worldwide.
- Most common in males age 20-24 years and females age 15-19 years.
- The proportion of penicillin-resistant organisms may reach 15% or higher in certain areas in Canada.
- Quinolone resistance in Canada has been steadily increasing; quinolone resistance in certain regions of Canada is significantly higher than the national rate.
- Continued monitoring for antimicrobial resistance is important to prevent the spread of drug-resistant gonorrhea and to ensure high cure rates for this treatable infection.

Susceptibility
General, re-infection is common.

Risk factors include:
- sexual contact with a person with proven infection or a compatible syndrome;
- unprotected sex with a partner from a highly endemic area (either international or within Canada);
- previous gonorrhea and other STI infection;
Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015

Section: 5-30

Page 6 of 9

- vulnerable populations (for example street-involved youth, commercial sex workers and their sexual partners, sexually active youth <25 years of age with multiple partners, men who have unprotected sex with men);
- substance use.

Methods of Control

Preventive Measures
Refer to Introduction and General Considerations of STI section of manual for information that should be shared for education and high-risk groups/activities that should be considered.

Every newborn in a hospital receives preventative treatment for ophthalmia neonatorum with erythromycin ophthalmic prophylaxis or another therapeutic agent considered to be a suitable substitute.

Immunization
Currently no vaccine for N. gonorrhoea.

Control of Patient
Treatment of gonorrhea is indicated for the following:
- all confirmed or suspected cases must be treated;
- all patients treated for gonorrhea should also be treated for chlamydial infection, unless test results for chlamydia are negative.

Patients and contacts should abstain from unprotected intercourse until treatment of both partners is complete (i.e., 7 days after completion of a multiple-dose treatment or for 7 days after single-dose therapy).
- Increasing gonococcal antimicrobial resistance being observed in Canada. In response to this, the Public Health Agency of Canada has changed the treatment recommendations as of December 2011.
- See Attachment – STI Treatment Guidelines for reference, however, the latest version of the Canadian Guidelines on Sexually Transmitted Infections should be referred to for current treatment guidelines: http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php.
Referrals
Consider additional testing for STI pathogens based on the risk assessment found in the Introduction and General Considerations of this section.

Control of Contacts
Due to the changing epidemiology of this disease, case finding and contact tracing are critical in the control of gonococcal infections. The following contacts must be located, clinically evaluated and treated:

- all sexual partners of cases within the past 90 days prior to symptom onset or date of diagnosis if asymptomatic, if no partners within this time frame, last sexual partner;
- parents of infected neonates;
- persons implicated in sexual abuse cases.

Contacts should receive clinical evaluation, testing, treatment and health education. Contacts should abstain from unprotected intercourse until treatment of both partners is complete (7 days after completion of single dose therapy).
Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015

Follow-up
Repeat screening is recommended in 6 months. Follow up cultures for test of cure are indicated approximately 4-5 days following completion of therapy. This must be completed in the following circumstances:

- treatment failure has occurred previously;
- antimicrobial resistance to therapy is documented;
- re-exposure to untreated partner;
- where compliance is unknown;
- if an alternative treatment has been used;
- in all prepubertal children;
- in all pregnant women;
- in cases of PID or disseminated gonococcal infection;
- quinolones were administered for treatment and there was no previous antimicrobial testing done;
- there is concern over a false-positive non-culture test result.

NAATs are not recommended for test of cure. If this is the only test available, it should be performed at least 4 weeks following completion of therapy to avoid false-positive results due to the presence of non-viable organisms. Positive NAAT test results within 30 days of treatment should be considered a duplicate case unless re-infection is likely to have occurred.

Antimicrobial susceptibility testing is required for all isolates from positive (test of cure) follow-up cultures and treatment failures.
Sexually Transmitted Infections

Gonococcal Infections

Date Reviewed: May, 2015  
Section: 5-30
Page 9 of 9

References


Sexually Transmitted Infections

Lymphogranuloma Venereum (LGV)

Reviewed: July, 2010

Section: 5-60

Page 1 of 7

Notification Timeline:
From Lab/Practitioner to Public Health: Within 72 hours.
From Public Health to Saskatchewan Ministry of Health: Within 2 weeks

Public Health Follow-up Timeline: Initiate within 72 hours.

Infectious Agent
Bacterial infection caused by *Chlamydia trachomatis*, serovars L1, L2, L3.

Case Definition (Public Health Agency of Canada, 2010)

Confirmed Case:
Presence of *C. trachomatis* serotype L1, L2, L3 confirmed by DNA sequencing or restriction fragment length polymorphism (RFLP).

Probable Case:
Positive result on culture, nucleic acid amplification tests (NAAT) or serologic testing for *C. trachomatis* plus the presence of proctitis OR inguinal or femoral lymphadenopathy OR a sexual partner with LGV.

Identification

*Table 1. Manifestations*

<table>
<thead>
<tr>
<th>Primary LGV</th>
<th>incubation period 3-30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>small (1-6mm) painless papule at site of inoculation that may ulcerate</td>
</tr>
<tr>
<td></td>
<td>self limited and may go unnoticed in up to 50% of people</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary LGV</th>
<th>begins within 2-6 weeks of primary lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>often accompanied by significant systemic symptoms such as low-grade fever, chills, malaise, myalgia, arthralgia; occasionally accompanied by arthritis, pneumonitis or hepatitis/perihepatitis; rarely associated with cardiac involvement, aseptic meningitis and ocular inflammatory disease</td>
</tr>
<tr>
<td></td>
<td>abscesses and draining sinuses are possible (less than 1/3 of patients)</td>
</tr>
<tr>
<td></td>
<td>involves the lymph nodes and/or anus and rectum</td>
</tr>
</tbody>
</table>
Sexually Transmitted Infections

Lymphogranuloma Venereum (LGV)

Reviewed: July, 2010

Section: 5-60
Page 2 of 7

| Secondary LGV causing lymphadenopathy | • inguinal/femoral is the most common form and is characterized by painful inguinal and/or femoral lymphadenopathy (unilateral in 1/2 to 2/3 of cases), referred to as buboes
| • “groove sign” inguinal nodes above and femoral nodes below theinguinal ligament (once considered pathognomonic for LGV)
| • other lymphadenopathy may occur depending on site of inoculation (cervical lymphadenopathy following inoculation during oral sex) |
| Secondary LGV causing anorectal symptoms | • characterized by acute hemorrhagic proctitis
| • symptoms of proctocolitis
| • bloody, purulent or mucous discharge from the anus, as well as constipation are common |
| Tertiary LGV (chronic LGV occurring in 10-20% of untreated cases) | • more common in females than males
| • chronic inflammatory lesions lead to scarring:
| • lymphatic obstruction causing genital elephantiasis
| • genital and rectal strictures and fistulae
| • possible extensive destruction of genitalia |

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

Incubation Period
Variable with a range of 3-30 days for a primary lesion; if a bubo is the first manifestation, 10-30 days to several months.

Reservoir
Humans, often asymptomatic (particularly in females).

Mode of Transmission
Direct contact with open lesions of infected people, usually during sexual intercourse.

Period of Communicability
Variable, from weeks to years during presence of active lesions.

Communicable Disease Control Manual

Saskatchewan
Ministry of Health
**Specimen Collection and Transport**

Definitive diagnosis of LGV requires serovar-specific (confirmatory) testing using DNA sequencing or restriction fragment length polymorphism (RFLP). Clinicians will therefore need to request that testing be done for LGV specifically, as most laboratories will not automatically perform serovar typing. Saskatchewan Disease Control Lab (SDCL) will forward specimens on to National Microbiology Laboratory (NML) for typing.

Due to issues of cross-reactivity and difficulty with interpretation of test results, serological testing should not be used for diagnostic purposes in the absence of culture or NAAT.

Samples that can be taken include:
- swab (urethral, rectal or lesion) for culture,*
- urine specimen for NAAT;
- blood serum sent for complement fixation (CF) looking for high titre.

*For information on specimen sources and culture media refer to Attachment - Transport Media for Specific STIs.

**Table 2. Specimen Collection**

<table>
<thead>
<tr>
<th>Stage of infection</th>
<th>Sample Type</th>
<th>Tests</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Swab of Lesion</td>
<td>Culture or NAAT</td>
<td>Because the invasive nature of LGV has not yet manifested in the primary stage of the infection, serology at this stage is unlikely to be helpful.</td>
</tr>
</tbody>
</table>
## Sexually Transmitted Infections

### Lymphogranuloma Venereum (LGV)

Reviewed: July, 2010

<table>
<thead>
<tr>
<th>Stage of Infection</th>
<th>Sample Type</th>
<th>Tests</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary and Tertiary</td>
<td>Bubo aspirate</td>
<td>Culture or NAAT</td>
<td>Identification of <em>C. trachomatis</em> in bubo fluid is highly suggestive of LGV, even prior to or without identification of LGV serovars.</td>
</tr>
<tr>
<td></td>
<td>Rectal, Vaginal, Oropharyngeal, or Urethral Swab</td>
<td>Culture or NAAT</td>
<td>NAAT is not officially approved in Canada for use with rectal or oropharyngeal swabs. Repeat testing is advised to confirm a positive test.</td>
</tr>
<tr>
<td></td>
<td>Urine</td>
<td>NAAT</td>
<td></td>
</tr>
<tr>
<td>Serology</td>
<td></td>
<td>MIF* Test CF* Test for <em>C. trachomatis</em> positive</td>
<td>Because of the invasive nature of LGV, serology titres are in general significantly higher in LGV vs. non-LGV <em>C. trachomatis</em> infections.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High-titre (titre ≥1:256) serology is suggestive of LGV infection but is not definitive; low-titre (titre ≥1:64) serology does not eliminate possibility of past or current LGV infection.</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infection, 2010.

*MIF = microimmunofluorescence  * CF = complement fixation

### Occurrence

In general, an uncommonly reported sexually transmitted infection (STI) in Canada. It is endemic in parts of Africa, Asia, South America and the Caribbean. A relatively rare disease in industrialized countries; until recently, the majority of cases were acquired in endemic areas. There have been recent outbreaks in men who have sex with men (MSM) starting in the Netherlands in 2003, with reports of cases in Belgium, France, Germany, Sweden, the U.K., the U.S., and Canada.
LGV may enhance the transmission and acquisition of HIV, other STIs and bloodborne pathogens.

The national LGV rate is unknown; however, a national enhanced surveillance system was initiated in February 2005 by the Public Health Agency of Canada in partnership with provincial and territorial public health departments.

Methods of Control

Preventive Measures
Refer to Introduction and General Considerations of STI section of manual for information that should be shared for education and high-risk groups/activities that should be considered.

*The Hospital Standards Regulations*\(^1\) indicates, “...every newborn in a hospital receives preventative treatment for ophthalmia neonatorum with erythromycin ophthalmic prophylaxis or another therapeutic agent considered to be a suitable substitute.”

Immunization
Currently no vaccine for *C. trachomatis*.

Control of Client
Refer to *Introduction and General Considerations of STI section* of manual for Risk Assessment. This should be used for taking client’s history.

Additional information should be gathered regarding history of travel both, outside and within Canada. Information that should be shared for education and high risk groups/activities that should be considered.

Treatment/Supportive Therapy
See Attachment - STI Treatment Guidelines for reference, however, the latest version of the Canadian Guidelines on Sexually Transmitted Infections should be referred to for current treatment guidelines.

\(^1\) *The Hospital Standards Regulations*, 21 Sep 2007 SR 86/2007 s12.
Referrals
Consider additional testing for STI pathogens based on the risk assessment found in the Introduction and General Considerations of this section.

Control of Contacts/Contact Investigation
Treatment of partners:
- Sexual partners from the last 60 days prior to symptom onset, or date of diagnosis where asymptomatic, should be contacted, tested and treated empirically (regardless of whether signs/symptoms are present) as follows:
  - azithromycin 1g PO in a single dose;
  - doxycycline 100 mg PO bid for 7 days.
- Should test results confirm an LGV infection, treat as recommended for cases above.

If there is no partner during this period, the last partner should be tested and treated.

Follow-up
Patients should be followed until chlamydial tests are negative (test of cure) and the patient has clinically recovered. Test of cure should be performed 4 weeks after the completion of effective treatment to avoid false-positive results due to the presence of non-viable organisms (especially if using NAAT).

Serology should not be used to monitor treatment response, as the duration of antibody response has not been defined.
- Surgery may be required to repair genital/rectal damage of tertiary LGV.
Sexually Transmitted Infections

Lymphogranuloma Venereum (LGV)

Reviewed: July, 2010

References


Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Notification Timeline:
- From Lab/Practitioner to Public Health: Within 48 hours.
- From Public Health to Saskatchewan Ministry of Health: Within 2 weeks.

Public Health Follow-up Timeline: Initiate within 72 hours.

General information on prevention and screening is included in the Sexually Transmitted Infections Introduction and General Considerations. Please refer to this section for additional general information.

Infectious Agent
Treponema pallidum, a spirochete bacterium.

Case Definition
Primary Syphilis
Confirmed Case (Public Health Agency of Canada, 2008)
Laboratory confirmation of infection:
- identification of Treponema pallidum by dark-field microscopy, fluorescent antibody, nucleic acid testing or equivalent examination of material from a chancre or a regional lymph node;
  OR
- presence of one or more typical lesions (chancre), and reactive treponemal serology, regardless of non-treponemal test reactivity, in individuals with no previous history of syphilis;
  OR
- presence of one or more typical lesions (chancre) and at least a 4-fold (e.g., 1:8 to 1:32) increase in the titre over the last known non-treponemal test in individuals with a past history of syphilis treatment.

Suspect Case (Saskatchewan Ministry of Health, 2013)
- a reactive serological test (both treponemal and non-treponemal);¹
  OR
- presence of one or more typical lesions (chancre) during the past three months regardless of treponemal serology or non-treponemal test reactivity;
  AND

¹ A second serological sample to identify a RPR titre change has not been taken yet or waiting for results.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70

Page 2 of 18

- sexual contact with a lab-confirmed or suspect infectious stage syphilis partner during the past six months.  

Secondary Syphilis

Confirmed Case (Public Health Agency of Canada, 2008)

Laboratory evidence of infection:

- identification of *T. pallidum* by dark-field microscopy, fluorescent antibody, nucleic acid testing or equivalent examination of mucocutaneous lesions, condylomata lata and reactive serology (non-treponemal and treponemal);
  
  OR

- presence of typical mucocutaneous lesions, rash (especially on palmar aspects of hands, soles of feet/trunk), alopecia, loss of eyelashes and lateral third of eyebrows, iritis, generalized lymphadenopathy, fever, malaise or splenomegaly, 
  
  AND either a reactive serology (non-treponemal and treponemal) OR a fourfold (e.g., 1:8 to 1:32) or greater increase in titre over the last known non-treponemal test.

NOTE: The possibility of a prozone reaction should be considered in individuals who are suspected of having secondary syphilis but whose non-treponemal test is non-reactive.

Suspect Case (Saskatchewan Ministry of Health, 2013)

- presence of typical signs or symptoms of secondary syphilis (e.g., mucocutaneous lesions, alopecia, loss of eyelashes and lateral third of eyebrows, iritis, generalized lymphadenopathy, fever, malaise or splenomegaly);
  
  AND

- reactive non-treponemal serology titre greater than or equal to 4.
  
  OR

- presence of typical signs or symptoms of secondary syphilis (e.g., mucocutaneous lesions, alopecia, loss of eyelashes and lateral third of eyebrows, iritis, generalized lymphadenopathy, fever, malaise or splenomegaly);

---

2 Six months allows for sexual contact during a three-month incubation (transmission) period of the source person plus an ensuing three-month incubation period of the case being reported.

3 Prozone reaction is a false negative rapid plasma reagin (RPR) from the presence of excess antibody. The antigen-antibody reaction is blocked. Occurs in approximately 1% of secondary syphilis cases. Lab should be notified if this is a concern.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70
Page 3 of 18

AND

• sexual contact with a lab-confirmed or suspect infectious stage partner in the past nine months.\(^4\)

*Early Latent Syphilis (≤ 1 year after infection)*

**Confirmed Case** (Public Health Agency of Canada, 2008)

Laboratory confirmation of infection:

• an asymptomatic patient with reactive serology (non-treponemal and/or treponemal) who within the past 12 months had **one** of the following:
  • non-reactive serology;
  • symptoms suggestive of primary or secondary syphilis;
  • exposure to a sexual partner with primary, secondary or early latent syphilis.

**Suspect Case** (Saskatchewan Ministry of Health, 2013)

An individual without symptoms of primary or secondary syphilis, **AND** has evidence of having acquired the infection within the previous 12 months based on **one or more** of the following criteria:

• reactive serology (non-treponemal and treponemal) tests from a person whose only exposure occurred within the preceding 12 months;
• documented seroconversion or four-fold or greater increase in the titre of a non-treponemal test during the previous 12 months;
• has a RPR titre of ≥ 1:16 and is a member of (or has had sexual partners in the previous 12 months from) groups at known increased risk of syphilis infection.

**OR**

An individual who has had symptoms of primary or secondary syphilis within the past 12 months:

• regardless of treponemal serology or non-treponemal test reactivity; **AND**
• is a member of (or has had sexual partners in the previous 12 months from) groups at known increased risk of syphilis.

---

\(^4\) Nine months allows for sexual contact during a three-month incubation (transmission) period after first contact with a source person plus an ensuing six-month infected period of the case being reported.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70

Page 4 of 18

Late Latent Syphilis (> 1 year after infection or of unknown duration)

**Confirmed Case** (Public Health Agency of Canada, 2008)

Laboratory confirmation of infection:

- an asymptomatic patient with persistently reactive treponemal serology (regardless of non-treponemal serology reactivity) who does not meet the criteria for early latent disease and who has not been previously treated for syphilis.

Infectious Neurosyphilis (< 1 year after infection)

**Confirmed Case** (Public Health Agency of Canada, 2008)

Laboratory confirmation of infection:

- fits the criteria of Primary Syphilis, Secondary Syphilis OR Early Latent Syphilis AND one of the following:
  - reactive CSF-VDRL (Venereal Disease Research Laboratory) in non-bloody cerebrospinal fluid (CSF);
  - clinical evidence of neurosyphilis AND either elevated CSF leukocytes OR elevated CSF protein in the absence of other known causes.

Non-Infectious Neurosyphilis (> 1 year after infection)

**Confirmed Case** (Public Health Agency of Canada, 2008)

Laboratory confirmation of infection:

- reactive treponemal serology (regardless of non-treponemal serology reactivity) AND one of the following:
  - reactive CSF-VDRL in non-bloody cerebrospinal fluid (CSF);
  - clinical evidence of neurosyphilis AND either elevated CSF leukocytes OR elevated CSF protein in the absence of other known causes.

Tertiary Syphilis Other Than Neurosyphilis

**Confirmed Case** (Public Health Agency of Canada, 2008)

Laboratory confirmation of infection:

- reactive treponemal serology (regardless of non-treponemal test reactivity) together with characteristic abnormalities of the cardiovascular system, bone, skin or other structures, in the absence of other known causes of these abnormalities (*T. pallidum* is rarely seen in these lesions although, when present, is diagnostic); AND
- no clinical or laboratory evidence of neurosyphilis.
Early Congenital Syphilis (within 2 years of birth)
Confirmed Case (Saskatchewan Ministry of Health, 2013)
Laboratory confirmation of infection:

- identification of *T. pallidum* by dark-field microscopy, fluorescent antibody or equivalent examination of material from nasal discharges, skin lesions, placenta, umbilical cord or autopsy material of a neonate (up to 4 weeks of age);  
  OR
- reactive serology (non-treponemal and treponemal) from venous blood (not cord blood) in an infant/child with clinical, laboratory or radiographic evidence of congenital syphilis,\(^5\) regardless of maternal treatment status;  
  OR
- detection of *Treponema pallidum* DNA in an appropriate clinical specimen;  
  OR
- infant’s RPR titre is 4-fold or greater higher than the mother’s at birth, or there is a 4-fold rise in the infant RPR titre;  
  AND
- persistently reactive treponemal serology in a child between 18 and 24 months of age (regardless of maternal treatment status).

Probable Case (Saskatchewan Ministry of Health, 2013)

- Reactive serology (non-treponemal and treponemal) from a venous blood (not cord blood) in an infant/child without clinical nor other laboratory, nor radiographic evidence of congenital syphilis\(^5\) whose mother had untreated or inadequately treated\(^6\) syphilis at delivery.

---

\(^5\) Clinical, laboratory or radiographic evidence of congenital syphilis on physical examination (e.g., rash, hepatosplenomegaly), evidence of congenital syphilis on radiographs of long bones, a reactive CSF VDRL, an elevated CSF count or protein without other cause. NOTE: neonates may not display clinical manifestations of congenital syphilis and may meet laboratory criteria only.

\(^6\) Inadequate treatment consists of any non-penicillin therapy or penicillin administered during pregnancy but less than 30 days before delivery.
Syphilitic Stillbirth

**Confirmed Case** (Saskatchewan Ministry of Health, 2013)
- A fetal death that occurs after 20 weeks gestation where the mother had untreated or inadequately treated syphilis at delivery;
- Laboratory confirmation of infection (e.g., detection of *T. pallidum* DNA in an appropriate clinical specimen, fluorescent antibody or equivalent examination of material from placenta, umbilical core of autopsy material).

**Probable Case** (Saskatchewan Ministry of Health, 2013)
- A fetal death that occurs after 20 weeks gestation where the mother had untreated or inadequately treated infectious syphilis at delivery with no other cause of stillbirth established.

**NOTE:** For reporting purposes, syphilitic stillbirths should be reported as cases of congenital syphilis.

**Identification**
After initial invasion, the syphilis organism multiplies rapidly and disseminates widely. The organism spreads through the perivascular lymphatics and then the systemic circulation before clinical development of the primary lesion. The primary lesion, containing infectious treponemes, arises within hours after infection and persists throughout primary and secondary disease. When untreated, syphilis is a lifelong infection that progresses in through 4 stages (Euerle, 2012).

---

7 Inadequate treatment consists of any non-penicillin therapy or penicillin administered during pregnancy but less than 30 days before delivery.
## Manifestations

**Table 1. Manifestations**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical Manifestations</th>
<th>Incubation Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td>Chancre, regional lymphadenopathy (localized reaction)</td>
<td>3 weeks (3-90 days)</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td>Rash, fever, malaise, lymphadenopathy, mucous lesions, condyloma lata, alopecia, meningitis, headaches, uveitis, retinitis (systemic reaction)</td>
<td>2-12 weeks (2 weeks to 6 months)</td>
</tr>
<tr>
<td><strong>Early Latent</strong></td>
<td>Asymptomatic</td>
<td>Early: &lt; 1 year</td>
</tr>
<tr>
<td><strong>Late Latent</strong></td>
<td></td>
<td>Late: ≥ 1 year</td>
</tr>
<tr>
<td><strong>Tertiary</strong></td>
<td><strong>Cardiovascular syphilis</strong></td>
<td>10-30 years</td>
</tr>
<tr>
<td></td>
<td>Aortic aneurysm, aortic regurgitation, coronary artery ostial stenosis</td>
<td></td>
</tr>
<tr>
<td><strong>Neurosyphilis</strong></td>
<td>Ranges from asymptomatic to symptomatic with headaches, vertigo, personality changes, dementia, ataxia, presence of Argyll Robertson pupil</td>
<td>&lt; 2 years-20 years</td>
</tr>
<tr>
<td><strong>Gumma</strong></td>
<td>Tissue destruction of any organ; manifestations depend on site involved</td>
<td>1-46 years (most cases 15 years)</td>
</tr>
<tr>
<td><strong>Congenital</strong></td>
<td><strong>Early</strong></td>
<td>Onset &lt; 2 years</td>
</tr>
<tr>
<td></td>
<td>2/3 may be asymptomatic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fulminant disseminated infection, mucocutaneous lesions, osteochondritis, anemia, hepatosplenomegaly, neurosyphilis</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Late</strong></td>
<td>Persistence &gt; 2 years after birth</td>
</tr>
<tr>
<td></td>
<td>Interstitial keratitis, lymphadenopathy, hepatosplenomegaly, bone involvement, anemia, Hutchinson’s teeth, neurosyphilis</td>
<td></td>
</tr>
</tbody>
</table>

Source: Adapted from Canadian Guidelines on Sexually Transmitted Infections 2010.

NOTE: Infectious – primary, secondary and early latent as incubation period 12 months or less.
Non-infectious – late latent, tertiary, congenital as incubation period > or = 1 year.
Sexually Transmitted Infections

Syphilis

Incubation Period
Can be between 3 days to 3 months, most commonly 3 weeks. See Table 1 above.

Reservoir
Human.

Mode of Transmission
The primary mode of transmission is by vaginal, anal and oral sexual contact. Primary, secondary and early latent stages are considered infectious, with an estimated risk of transmission per partner of around 60%. Early latent syphilis is considered infectious because of the 25% chance of relapse to secondary stage. Kissing, sharing of needles and injection equipment, blood transfusion and accidental inoculation have rarely been reported as routes of transmission. Breastfeeding by mothers with primary or secondary lesions of syphilis carries a theoretical risk of transmission of syphilis to the baby.

Period of Communicability
Communicability exists when moist mucocutaneous lesions of primary and secondary syphilis are present (regardless of treatment). The distinction between the infectious primary and secondary stages and the non-infectious early latent stage of syphilis is somewhat arbitrary with regard to communicability, since primary and secondary stage lesions may not be apparent to the infected individual. Lesions of secondary syphilis may recur with decreasing frequency up to 4 years after infection, but transmission of infection is rare after the first year.

In many countries, infectious early syphilis is usually defined as ending after the first year of infection.

The majority of infants with congenital syphilis are infected in utero, but they can also be infected by contact with an active genital lesion at the time of delivery; the risk of transmission is much greater when the mother has untreated primary, secondary or early latent syphilis in pregnancy than if she has late latent syphilis. Infected infants may have moist mucocutaneous lesions that are more widespread than in adult syphilis and are a potential source of infection.
Specimen Collection and Transport
The laboratory diagnosis of syphilis includes the following:

1. Serology – the mainstay for diagnosis of syphilis. Submit 5 ml of serum. An IgG and IgM for treponemal antibodies is conducted initially as a screening test and if this is positive then the TPPA and RPR titre is performed to confirm the diagnosis and identify acute disease.

2. The PRP titre is the objective measure of disease which is used to determine/monitor treatment success/failure.
   - NTT (RPR, VDRL, and ART) – Nonspecific antibodies develop 4-8 weeks following infection and seroreactivity occurs in 70% of patients within 2 weeks of developing a chancre and in 100% of patients with secondary and latent disease.
   - Treponemal tests (FTA-ABS, TP-PA treponema, TP-HA treponema, EIA, MHA-TP)\(^8\) – measure antibodies specific for \(T. pallidum\). These tests become positive soon after infection and typically remain positive for life, despite adequate treatment. Unfortunately, this test does not differentiate between treponemal sub species such as yaws, pinta and bejel (important for follow up of immigrants).

In high-risk patients, a single high titre of 1:8 or greater is consistent with a presumptive case and clinicians will often treat the patient on the basis of this single result.

A significant change is a two-fold increase or decrease in the titre. Patients with titres of 1:8 or greater should be considered significant and should be reviewed with the regional Medical Health Officer (MHO). The serology needs to be repeated in 2 to 3 months to detect a two fold or greater change in titre to confirm acute disease. Titres after treatment should decline to seronegative or to a stable low titre, such as 1:4.

3. Microscopy – for painless chancre de-roof the lesion, spread serous exudate on a microscopic slide (covering an area the size of a dime), air dry and submit to the laboratory. It will be stained for spirochetes.

See Attachment – SDCL Syphilis Tests and Interpretation.

\(^8\) FTA-ABS fluorescent treponemal antigen-absorbed, TP-PA \(T. pallidum\) particle agglutination, MHA-TP microhemagglutination \(T. pallidum\).
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70

Page 10 of 18

Occurrence
Infectious syphilis is the least common of the three nationally reportable sexually transmitted infections (STIs). Cases are usually sporadic with occasional clusters. In Canada, most of the clusters have been related to the sex trade and in men who have sex with men; recently in Saskatchewan and Alberta there has been an increase in heterosexual transmission.

Susceptibility
Previous infection with syphilis does not induce long-term immunity; re-infection is possible.

Methods of Control

Preventive Measures
The Sexually Transmitted Infections Introduction and General Considerations section of the manual highlights topics for client education that should be considered as well as provides information on high-risk groups and activities.

Because untreated syphilis in a pregnant woman can infect the fetus and result in fetal death or congenital syphilis, every pregnant woman should be routinely tested for syphilis in the first trimester. Women at increased risk for syphilis should be screened again later in the pregnancy.

Special Considerations in Pregnant Women and Newborn Infants
- Given the resurgence of syphilis in Canada, universal screening of all pregnant women continues to be important and remains the standard of care in most jurisdictions.
- Screening should ideally be performed in the first trimester and repeated at 28-32 weeks and again at delivery in women at high risk of acquiring syphilis (See Risk Factors, below) or in areas experiencing heterosexual outbreaks of syphilis.
- Any woman delivering a stillborn infant at ≥ 20 weeks gestation should be screened for syphilis.
- No newborn should be discharged from hospital prior to confirmation that either the mother or newborn infant has had syphilis serology undertaken during pregnancy or at the time of labour or delivery.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70

Page 11 of 18

- Infants presenting with signs or symptoms compatible with early congenital syphilis should be tested for syphilis.

Management of Case

History

Complete an assessment of the case using the Attachment - Risk Assessment Questionnaire in the STIs section of this manual. Risk factors that are most often associated with syphilis include:

- men who have sex with men (MSM);
- contact with a known case;
- street involvement;
- sex trade;
- injection drug use;
- multiple sexual partners;
- history of previous diagnosis of syphilis, other STIs or HIV;
- internet partnering;
- anonymous liaisons.

There have been outbreaks in certain communities throughout Canada and within Saskatchewan. History of travel may also be useful in determining potential source and exposure locations.

Immunization

There is currently no vaccine available for syphilis prevention. Cases and contacts should be offered any immunizations (e.g., hepatitis B vaccine, etc.) they may be eligible for based on the Saskatchewan Immunization Manual, Chapter 7.9

Treatment/Supportive Therapy

See Attachment – STI Treatment Guidelines for reference, however, the latest version of the Canadian Guidelines on Sexually Transmitted Infections should be referred to for current treatment guidelines.

9 http://www.ehealthsask.ca/services/manuals/Documents/sim-chapter7

Communicable Disease Control Manual
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section:  5-70
Page 12 of 18

Period of Abstinence
Cases are infectious until mucocutaneous lesions are healed. To prevent continued spread of infection, cases should abstain from sexual contact until the lesions are completely healed and it has been 2 weeks since they received their final dose of treatment (if multiple doses were required – i.e., co-infected with HIV, etc.).

Follow-up Serology
Since there is no test of cure, follow-up serology (non-treponemal tests [RPR]) is important to ensure that treatment has been effective. The following table indicates the recommended time frames for post-treatment serology to be done.

Table 2. Monitoring of Serologic Tests and Other Follow Up

<table>
<thead>
<tr>
<th>Primary, secondary, early latent</th>
<th>(1), 3, 6, 12 months after treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Late latent, tertiary</td>
<td>12 and 24 months after treatment.</td>
</tr>
<tr>
<td>Neurosyphilis</td>
<td>6, 12 and 24 months after treatment.</td>
</tr>
<tr>
<td></td>
<td>Patients with CSF abnormalities require follow up CSF at 6 monthly intervals until normalization of CSF parameters. Other clinical follow up may be indicated on a case by case basis.</td>
</tr>
<tr>
<td>HIV-infected (any stage)</td>
<td>(1), 3, 6, 12 and 24 months after treatment and yearly thereafter.</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

Management of infants born to pregnant women with reactive treponemal tests during pregnancy is complex and outlined in the Canadian Guidelines on Sexually Transmitted Infections and should be referred to directly for guidance. Refer to http://origin.phac-aspc.gc.ca/std-mts/sti-its/pdf/510syphilis-eng.pdf.

Special Considerations

HIV infection
- Persons co-infected with HIV may require a longer course of treatment, as well as closer and longer follow-up.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70
Page 13 of 18

Pregnancy

- All women newly diagnosed with syphilis during pregnancy should receive treatment appropriate to their stage of disease, with the exception of secondary syphilis in late pregnancy, where despite the administration of the recommended penicillin regimen, as many as 14% will have a fetal death or deliver infants with clinical evidence of congenital syphilis. Some experts recommend that primary, secondary, and early latent cases in pregnancy be treated with two doses of benzathine penicillin G 2.4 million units 1 week apart; the efficacy of this regimen in preventing fetal syphilis is not known.
- Retreatment during pregnancy is not necessary unless there is clinical or serologic evidence of new infection (four-fold rise in a non-treponemal test titre) or history of recent sexual contact with early syphilis.
- Erythromycin is the least effective agent for the treatment of syphilis and does not penetrate the CSF or placental barrier well; it is therefore not recommended in pregnancy.
- If the mother is > 20 weeks gestation, an ultrasound should be performed and she should be managed with an obstetrician/maternal-fetal medicine specialist; if fetal abnormalities are identified, the mother should be hospitalized for treatment and fetal monitoring.
- All babies born to mothers diagnosed with syphilis should be assessed at delivery by a pediatrician or pediatric specialist (e.g., infectious diseases), and if a maternal non-penicillin regimen was used, consideration should be given to treating the baby empirically for congenital syphilis.
- In cases where a child is born to a mother who was diagnosed with syphilis in pregnancy, and where the child is placed under the care of child protection services, medical information about the mother’s diagnosis may be critical to the ongoing protection and monitoring of the infant’s health. It is important to facilitate the collection and disclosure of relevant health information, in accordance with provincial/territorial requirements, in order to allow appropriate follow-up care.

Congenital syphilis

- Infected infants are frequently asymptomatic at birth and may be seronegative if maternal infection occurred late in gestation.
Infants should be treated at birth:
- if symptomatic;
- if the infant’s non-treponemal titre (RPR) is at least four-fold (2 tubes) higher than the mother’s;
- if maternal treatment was inadequate, did not contain penicillin, is unknown or occurred in the last month of pregnancy, or if maternal serologic response is inadequate;
- if adequate follow-up of the infant cannot be ensured.

**Jarisch-Herxheimer reaction (Post-treatment reaction)**

- Patients should be made aware of this possible reaction to treatment, especially with penicillin.
- An acute febrile illness with headache, myalgia, chills, rigours generally occurring within 8-12 hours and resolving within 24 hours.
- Common in early syphilis, but usually not clinically significant unless there is neurologic or ophthalmic involvement or in pregnancy where it may cause fetal distress and premature labour.
- Not a drug allergy.
- Can be treated with antipyretics.
- Steroids may be indicated for the management of severe reactions but should be used in consultation with a colleague experienced in this area.

**Referrals**

- Consider additional testing for other STI or CD pathogens based on the risk assessment found in the *Introduction and General Considerations* of this section.
- Clients may benefit from referrals to other care providers such as infectious disease specialists or to supportive services as indicated (see *Introduction and General Considerations*).

**Management of Contacts**

**Partner Notification**
Partner notification for syphilis is based on the stage of syphilis in the index case. Any sexual or perinatal contacts of the case that occurred within the following time periods must be located, tested and treated if serology is reactive.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Table 3. Partner Notification

<table>
<thead>
<tr>
<th>Stage of syphilis (Index Case)</th>
<th>Time Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary syphilis</td>
<td>3 months prior to the onset of symptoms.</td>
</tr>
<tr>
<td>Secondary syphilis</td>
<td>6 months prior to the onset of symptoms.</td>
</tr>
<tr>
<td>Early latent</td>
<td>1 year prior to the diagnosis.</td>
</tr>
<tr>
<td>Late latent</td>
<td>Assess marital or other long-term partners and</td>
</tr>
<tr>
<td></td>
<td>children as appropriate.</td>
</tr>
<tr>
<td>Congenital</td>
<td>Assess mother and her sexual partner(s)</td>
</tr>
<tr>
<td>Stage undetermined</td>
<td>Assess/consult with a colleague experienced in</td>
</tr>
<tr>
<td></td>
<td>syphilis management.</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.

Prophylaxis/Abstinence/Follow-up

All contacts should be tested for syphilis to determine their baseline status. Follow-up serology should be based on the date of last sexual exposure to syphilis. This date should be included on Contact Referral forms when referring a contact to an outside health authority or jurisdiction.

Management of Contacts to a Lab Confirmed Case of Infectious Syphilis

Sexual contact with case occurred in the last 30 days:

Treatment

- These contacts should all be offered epidemiologic (presumptive) treatment with a single dose of bicillin (if no penicillin allergy) at the same time their baseline serology is collected (this should be done at their first appointment).

Period of Abstinence

- Clients should be encouraged to abstain from all sexual contact with others for a full 2 weeks following the treatment.
- If the client has any lesions, the 2-week period of abstinence should be extended until all lesions have healed.

Condoms should be advised and encouraged for all sexual encounters.

10 The date of exposure should be included on the contact referral form. If this date is unknown date of contact notification should be used.
Sexually Transmitted Infections

Syphilis

Follow-up Serology

- Treated clients should be asked to return for follow-up serology at 30 days post exposure (unless their initial baseline testing was conducted close to 30 days post exposure) and again at 90 days after their last encounter with the index case.

Sexual contact with case occurred 30 to 90 days previously and there is any risk that the contact will be lost to follow up before serologic results are available (or if baseline testing cannot be completed):

Treatment

- The contact should be offered epidemiologic (presumptive) treatment with a single dose of bicillin (if no penicillin allergy) at their initial visit. Baseline serology should also be collected at this first visit.

Period of Abstinence

- Clients should be encouraged to abstain from all sexual contact with others for 2 weeks since the treatment was given.
- If the client has any lesions, the 2-week period of abstinence should be extended until all lesions have healed.
  Condoms should be advised and encouraged for all sexual encounters.

Follow-up Serology

- Treated clients should be asked to return for follow-up serology at 90 days after their last encounter with the index case (as their initial baseline serology would have been collected more than 30 days after their last exposure).

Sexual contact occurred 30 to 90 days previously and there is no risk that the contact will be lost to follow up before serologic results are available:

Period of Abstinence

- Untreated clients should be advised and encouraged to abstain from sexual contact with others for the entire duration of the incubation period for syphilis – 90 days from their last encounter with the index case.
- If the client is treated at a later visit (based on results of follow-up serology), they should be encouraged to abstain from all sexual contact with others for 2 weeks following the treatment and if the client has any lesions, the 2-week period of abstinence should be extended until all lesions have healed.
  Condoms should be advised and encouraged for all sexual encounters.
Sexually Transmitted Infections

Syphilis

Follow-up Serology

- Clients should be asked to return for follow-up serology 60 days (unless their initial baseline testing was conducted close to 60 days post exposure) and 90 days after their last encounter with the index case.

Treatment

- Any treatment should be based on the results of their baseline and follow-up serology, stage and other considerations (see Table 3 above).

Education

All contacts should receive counselling regarding:

- communicability, incubation period, transmission, and signs and symptoms of syphilis;
- the risk for re-exposure;
- ways to reduce their future risk of exposure;
- the importance of abstinence during entire incubation period and until serologic testing at the end of the incubation period has been confirmed to be non-reactive;
- the need for follow-up serology and the timing of the serology;
- the follow-up recommended in the event that they develop signs and symptoms including abstaining from sexual contact until they have seen a physician/nurse (or health care provider) for re-assessment.

Outbreak

During an outbreak enhanced surveillance information on both cases and contacts and the risk factors associated with transmission should be captured. The attached Investigation Tools will assist in capturing both information that is routinely collected while investigating a new syphilis case, as well as additional information that will improve the understanding of the social networks driving the outbreak. See Attachments:

- Saskatchewan Syphilis Outbreak Investigation – Case Questionnaire.
- Saskatchewan Syphilis Outbreak Investigation – Contact Information Form.
- Information on completing the Syphilis Outbreak Investigation Tool.

Epidemic Measures

It may be prudent to intensify prevention and control measures. At risk populations may require alternate modes of intervention to reach them. This should be done in consultation with the MHO and Saskatchewan Ministry of Health.
Sexually Transmitted Infections

Syphilis

Reviewed: August, 2014

Section: 5-70

Page 18 of 18

References


### Sexually Transmitted Infections
### Attachment – Risk Assessment Questionnaire

**Date Reviewed:** July 2010  
**Section:** 5  
**Page 1 of 2**

<table>
<thead>
<tr>
<th>Category and elements</th>
<th>Important questions to guide your assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Relationship</strong></td>
<td></td>
</tr>
<tr>
<td>Present situation</td>
<td>• Do you have a regular sexual partner?</td>
</tr>
<tr>
<td></td>
<td>• If yes, how long have you been with this person?</td>
</tr>
<tr>
<td>Identify concerns</td>
<td>• Do you have any concerns about your relationship?</td>
</tr>
<tr>
<td></td>
<td>• If yes what are they (e.g., violence, abuse, coercion)?</td>
</tr>
<tr>
<td><strong>Sexual risk behaviour</strong></td>
<td></td>
</tr>
<tr>
<td>Number of partners</td>
<td>• When was your last sexual contact? Was that contact with your regular partner or with a different partner?</td>
</tr>
<tr>
<td></td>
<td>• How many different sexual partners have you had in the past 2 months? In the past year?</td>
</tr>
<tr>
<td>Sexual preference, orientation</td>
<td>• Are your partners men, women or both?</td>
</tr>
<tr>
<td>Are your partners men, women or both?</td>
<td>• Do you perform oral sex (i.e., do you kiss your partner on the genitals or anus)?</td>
</tr>
<tr>
<td></td>
<td>• Do you receive oral sex?</td>
</tr>
<tr>
<td></td>
<td>• Do you have intercourse (i.e., do you penetrate your partners in the vagina or anus [bum]? Or do your partners penetrate your vagina or anus [bum])?</td>
</tr>
<tr>
<td>Personal risk evaluation</td>
<td>• Have any of your sexual encounters been with people from a country other than Canada? If yes, where and when?</td>
</tr>
<tr>
<td></td>
<td>• How do you meet your sexual partners (when travelling, bathhouse, Internet)?</td>
</tr>
<tr>
<td></td>
<td>• Do you use condoms, all the time, some of the time, never?</td>
</tr>
<tr>
<td></td>
<td>• What influences your choice to use protection or not?</td>
</tr>
<tr>
<td></td>
<td>• If you had to rate your risk for STI, would you say that you are at no risk, low risk, medium risk or high risk? Why?</td>
</tr>
<tr>
<td><strong>STI history</strong></td>
<td></td>
</tr>
<tr>
<td>Previous STI screening</td>
<td>• Have you ever been tested for STI/HIV? If yes, what was your last screening date?</td>
</tr>
<tr>
<td>Previous STI</td>
<td>• Have you ever had an STI in the past? If yes, what and when?</td>
</tr>
<tr>
<td>Current concern</td>
<td>• When was your sexual contact of concern?</td>
</tr>
<tr>
<td></td>
<td>• If symptomatic, how long have you had the symptoms that you are experiencing?</td>
</tr>
</tbody>
</table>

Communicable Disease Control Manual
## Sexually Transmitted Infections

**Attachment – Risk Assessment Questionnaire**

Date Reviewed: July 2010

### Category and elements

<table>
<thead>
<tr>
<th>Category and elements</th>
<th>Important questions to guide your assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reproductive health history</strong></td>
<td></td>
</tr>
<tr>
<td>Contraception</td>
<td>• Do you and/or your partner use contraception? If yes, what? Any problems? If no, is there a reason?</td>
</tr>
<tr>
<td>Pap test</td>
<td>• Have you ever had an abnormal Pap test? If yes, when? Result if known.</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>• Have you ever been pregnant? If yes, how many times? What was/were the outcome(s) (number of live births, abortions, miscarriages)?</td>
</tr>
<tr>
<td><strong>Substance use</strong></td>
<td></td>
</tr>
<tr>
<td>Share equipment for injection</td>
<td>• Do you use alcohol? Drugs? If yes, frequency and type? If injection drug use, have you ever shared equipment? If yes, what was your last sharing date?</td>
</tr>
<tr>
<td>Sex under influence</td>
<td>• Have you had sex while intoxicated? If yes, how often?</td>
</tr>
<tr>
<td></td>
<td>• Have you had sex while under the influence of alcohol or other substances? What were the consequences?</td>
</tr>
<tr>
<td></td>
<td>• Do you feel that you need help because of your substance use?</td>
</tr>
<tr>
<td>Percutaneous risk other than drug injection</td>
<td>• Do you have tattoos or piercings? If yes, were they done using sterile equipment (i.e., professionally)?</td>
</tr>
<tr>
<td><strong>Psychosocial history</strong></td>
<td></td>
</tr>
<tr>
<td>Sex trade worker or client</td>
<td>• Have you ever traded sex for money, drugs or shelter?</td>
</tr>
<tr>
<td></td>
<td>• Have you ever paid for sex? If yes, frequency, duration and last event.</td>
</tr>
<tr>
<td>Sexual Abuse</td>
<td>• Have you ever been forced to have sex? If yes, when and by whom?</td>
</tr>
<tr>
<td></td>
<td>• Have you ever been sexually abused? Have you ever been physically or mentally abused? If yes, when and by whom?</td>
</tr>
<tr>
<td>Housing</td>
<td>• Do you have a home? If no, where do you sleep?</td>
</tr>
<tr>
<td></td>
<td>• Do you live with anyone?</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections, 2010.
Please see the following pages for the STI Notification Form.
ATTENTION: Saskatchewan Physicians

The purpose of this letter is to review the process of reporting and follow-up of sexually transmitted infections (i.e. gonorrhea, chlamydia). Saskatchewan has one of the highest rates of chlamydia in Canada. As part of a strategy to bring down STI rates in the province, we are asking for your assistance.

Steps to remember when a positive lab report is received:

- Notify the client as soon as possible.
- Treat chlamydia and gonorrhea with medications that are available at no cost through your local Public Health office. Prescriptions are not necessary.
- Give single dose medications by direct observed therapy to guarantee compliance.
- Inform cases to abstain from intercourse for 7 days following treatment and to practice safer sex with all partners to avoid re-infection.
- Ask all positive cases about their sexual contacts in the past three months, including names, addresses and phone numbers. Full information assists public health to locate contacts.
- Complete all sections of the “Confidential Notification of Sexually Transmitted Diseases” form included with the positive lab report.
- Forward the completed “Confidential Notification of Sexually Transmitted Infections” form to your local public health office within 72 hours if possible. Timelines assist public health to do follow up more effectively.

Where can medications be obtained?

- To set up an ordering schedule for your practice, phone your local Public Health office. Keep a supply on hand to ensure timely treatment.

What if the client cannot be reached?

- Notify Public Health as soon as possible. Public Health Nurses are available to assist in the location of cases and their contacts.

Did you know?

- Sexually Transmitted Infection Clinics offer testing and treatment of STIs. Clinics operate in Regina, Saskatoon, Prince Albert and North Battleford. Please call your local public health office for hours.
- Questions regarding the treatment of sexually transmitted infections can be directed to your local public health office or the Sexually Transmitted Infections Clinics.
- The “Saskatchewan Communicable Disease Control Manual” is available online at http://www.ehealthsask.ca/services/manuals/Pages/CDCManual.aspx

The successful management of sexually transmitted infections depends on the co-operative efforts of all involved in each step of the process. We appreciate your help in the identification and follow-up of these cases.

Office of the Chief Medical Health Officer
Population Health Branch

September 2015
### Confidential Notification of Sexually Transmitted Infections

**Please complete all sections.**

**FORMAT ALL DATES AS DAY/MONTH/YEAR.**

## A) CLIENT INFORMATION

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name &amp; Initial</th>
<th>Other Name/Alias</th>
<th>For Public Health use only – DATE RECEIVED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Full Resident Address (include postal code):**

<table>
<thead>
<tr>
<th>Phone #: ( ) Work ( ) cell ( ) home:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**On reserve? ( ) Yes ( ) No**

**If yes, indicate FN Community**

**Racial Ethnicity**

<table>
<thead>
<tr>
<th>Marital Status: ( ) S ( ) M ( ) Com Law ( ) Sep/Div</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**HSN**

<table>
<thead>
<tr>
<th>DOB <strong><strong><strong><strong><strong>/</strong></strong></strong></strong></strong>/________</th>
<th>Age ______</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) M</td>
<td></td>
</tr>
<tr>
<td>( ) F</td>
<td></td>
</tr>
</tbody>
</table>

**Is client pregnant? ( ) Y ( ) N**

**Comments:**

**Will index case be notifying contact? ( ) Yes ( ) No**

**If yes, date contact notified: _____/_____/______**

**Reg. partner ( ) Sex trade ( ) Marital/CL ( ) Casual**

**Relationship to client**

<table>
<thead>
<tr>
<th>( ) Marital/CL ( ) Casual ( ) Reg. partner ( ) Sex trade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Exposure Dates:**

<table>
<thead>
<tr>
<th>(1st) <strong><strong><strong><strong><strong>/</strong></strong></strong></strong></strong>/________ to <strong><strong><strong><strong><strong>/</strong></strong></strong></strong></strong>/________</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) Unprotected sex ( ) Protected sex</td>
</tr>
</tbody>
</table>

**Will the testing Physician/Nurse follow-up this contact? ( ) Yes ( ) No**

**If yes, date contact notified: _____/_____/______**

**Will index case be notifying contact? ( ) Yes ( ) No**

## B) SERVICE PROVIDER INFORMATION

**Name of Attending Physician or Nurse**

<table>
<thead>
<tr>
<th>Phone number:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Address:**

## C) INFECTION INFORMATION **(check ALL that apply)**

**Infection reported:**

<table>
<thead>
<tr>
<th>( ) Chlamydia ( ) Gonorrhea ( ) Syphilis, indicate STAGING: ______________________</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>( ) Other STI (see list on page 3):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

## D) LAB TESTING

**Reason client was tested:**

<table>
<thead>
<tr>
<th>( ) Health Provider Recommended ( ) Client Requested ( ) Clinical Sign &amp; Symptoms ( ) Other ____________________</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Hepatitis B Status**

<table>
<thead>
<tr>
<th>Antibody: ( ) pos ( ) neg ( ) unk</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) Azithromycin 1gm DOT* ( ) yes ( ) no</td>
</tr>
<tr>
<td>( ) Azithromycin 2gm DOT* ( ) yes ( ) no</td>
</tr>
<tr>
<td>( ) Cefixime 800 mg DOT* ( ) yes ( ) no</td>
</tr>
<tr>
<td>( ) Ceftriaxone 250 mg IM</td>
</tr>
<tr>
<td>( ) Amoxicillin 500 mg tid x 7d</td>
</tr>
<tr>
<td>( ) Bicillin ( ) 1st, ( ) 2nd, ( ) 3rd dose</td>
</tr>
<tr>
<td>( ) Erythromycin 333mg it tid x 7d or other dosage ___</td>
</tr>
<tr>
<td>( ) Doxycycline 100mg bid x 7d or other dosage ___</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date Treated Treated by whom:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

## E) TREATMENT **(check all that apply)**

**Sites Exposed:**

<table>
<thead>
<tr>
<th>( ) vagina/urethra ( ) rectum ( ) pharynx</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) No condom used ( ) Sex trade partner</td>
</tr>
<tr>
<td>( ) Condom failure ( ) Sex with sex trade partner</td>
</tr>
<tr>
<td>( ) Injection drug use ( ) Sexual assault</td>
</tr>
<tr>
<td>( ) Alcohol/drug use ( ) Internet partnering - indicate site:</td>
</tr>
<tr>
<td>( ) New partner within the last 3 months</td>
</tr>
<tr>
<td>( ) More than 2 partners in the last 3 months</td>
</tr>
<tr>
<td>( ) Casual sex while travelling outside of Canada</td>
</tr>
<tr>
<td>( ) Sex with a known STI case</td>
</tr>
<tr>
<td>( ) Street involved / homeless</td>
</tr>
<tr>
<td>( ) Infant born to infected mother</td>
</tr>
</tbody>
</table>

## F) EXPOSURE INFO **(check ALL that apply)**

**Reason for exposure:**

<table>
<thead>
<tr>
<th>( ) Education ( ) Hepatitis B immunization ( ) Contact follow up - complete Section H ( ) To order STI medications – indicate amount below:</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) Azithromycin ( ) Cefixime ( ) Ceftriaxone ( ) Amoxicillin ( ) Erythromycin ( ) Doxycycline ( ) Notification Forms</td>
</tr>
</tbody>
</table>

## G) REFERRAL TO PUBLIC HEALTH **(check all that apply)**

<table>
<thead>
<tr>
<th>( ) Education ( ) Hepatitis B immunization ( ) Contact follow up - complete Section H ( ) To order STI medications – indicate amount below:</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) Azithromycin ( ) Cefixime ( ) Ceftriaxone ( ) Amoxicillin ( ) Erythromycin ( ) Doxycycline ( ) Notification Forms</td>
</tr>
</tbody>
</table>

## H) SEXUAL PARTNER INFORMATION **Please include information on additional contacts on a separate sheet**

**Last Name / Alias / Maiden Name**

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name / Alias / Maiden Name</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Full Resident Address**

<table>
<thead>
<tr>
<th>Phone #: ( ) Work ( ) cell ( ) home:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**DOB __________/__________/________**

**Age ________ ( ) Male ( ) Female**

<table>
<thead>
<tr>
<th>Marital Status: ( ) S ( ) M ( ) Com Law ( ) Sep/Div</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Living with: ( ) Client ( ) Parents ( ) Other**

**Pregnant: ( ) Y ( ) N Place of Employment:**

**Name of School (if student):**

**Relation to client:**

<table>
<thead>
<tr>
<th>( ) Marital/CL ( ) Casual ( ) Reg. partner ( ) Sex trade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Exposure Dates:**

<table>
<thead>
<tr>
<th>(1st) <strong><strong><strong><strong><strong>/</strong></strong></strong></strong></strong>/________ to <strong><strong><strong><strong><strong>/</strong></strong></strong></strong></strong>/________</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ) Unprotected sex ( ) Protected sex</td>
</tr>
</tbody>
</table>

**Will the testing Physician/Nurse follow-up this contact? ( ) Yes ( ) No**

**If yes, date contact notified: ______/_____/______**

**Will index case be notifying contact? ( ) Yes ( ) No**

**Comments:**

## CD 66 - September 2015

Personal health information collected for the purpose of [reporting communicable disease] should be protected by your organization in accordance with Part III of The Health Information Protection Act (HIPA). As the trustee you have a duty to protect this information pursuant to section 16 of HIPA.
Notifiable Sexually Transmitted Infections

chancroid  human T lymphotropic virus, Types I and II
chlamydia (C. trachomatis)  lymphogranuloma venereum
gonococcal infections  neonatal/congenital herpes
granuloma inguinale  syphilis (all stages)
*HIV/AIDS  **hepatitis B, C & D

*Report HIV on Saskatchewan Ministry of Health’s HIV Case Report form.
# Sexually Transmitted Infections
## Attachment – Transport Media for Specific STIs

**Reviewed:** October, 2010  
**Section:** 5  
**Page 1 of 1**

### Specific STI | Swab Type: | Transport Medium
--- | --- | ---
**Chlamydia trachomatis** | Swab type: Copan nylon tipped, plastic shaft swab OR Fisher plastic polyester tipped swab or N/P malleable aluminum thin swabs  
**Source:** e.g., pharynx, rectal, vaginal, and/or conjunctiva | UTM-RT transport medium (supplied in package with swab) OR 2SP Chlamydia transport medium (glass vials, orange labeling “2SP”)

**Neisseria gonorrhoeae** | Swab type: Fisher plastic polyester tipped swab or N/P malleable aluminum thin swabs  
**Source:** e.g., pharynx, rectal, joint aspirate, vaginal, and/or conjunctiva | Amies transport medium with charcoal

**Lymphogranuloma Venereum (LGV)** | Swab type: Copan nylon tipped, plastic shaft swab OR Fisher plastic polyester tipped swab or N/P malleable aluminum thin swabs  
**Source:** e.g., lesion, bubo aspirate, rectal, vaginal and/or urethral swab | UTM-RT transport medium (supplied in package with swab) OR 2SP Chlamydia transport medium (glass vials, orange labeling “2SP”)

**Herpes Simplex Virus** | Swab type: Copan nylon tipped, plastic shaft swab OR Fisher brand plastic polyester tipped swab  
**Source:** suspected herpes lesions | UTM-RT transport medium (supplied in package with swab) OR Viral transport medium (pink fluid in clear plastic vial; orange label; prominent expiry date)

Source: Paul Levett, Assistant Clinical Director, Saskatchewan Disease Control Laboratory, Oct 2010

---

Communicable Disease Control Manual
Chlamydia

- In the absence of a contraindication, the following treatment options are recommended:

Table 1. Chlamydia. Adults (non-pregnant and non-lactating): Urethral, endocervical, rectal, conjunctival infection

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Azithromycin 1 g PO in a single dose if poor compliance is expected OR • Doxycycline 100 mg PO bid for 7 days</td>
<td>• Ofloxacin 300 mg PO bid for 7 days OR • Erythromycin 2 g/day PO in divided doses for 7 days† OR • Erythromycin 1 g/day PO in divided doses for 14 days†</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections 2010.

†If vomiting occurs more than 1 hour post-administration, a repeat dose is not required.
‡Erythromycin dosages refer to erythromycin base. Equivalent dosages of other formulations may be substitute (with the exceptions of the estolate formulation being contraindicated in pregnancy). If erythromycin has been used for treatment, test of cure should be performed 4 weeks after completion of therapy.

Notes:
- In Saskatchewan azithromycin is generally the preferred treatment due to poor compliance of multiday treatments.

Table 2. Chlamydia. Children

<table>
<thead>
<tr>
<th>First week of life</th>
<th>Infants ≤ 2000 g</th>
<th>Infants &gt; 2000 g</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Erythromycin 20 mg/kg/day PO in divided doses for at least 14 days†</td>
<td>• Erythromycin 30 mg/kg/day PO in divided doses for at least 14 days†</td>
</tr>
</tbody>
</table>

>1 week to 1 month | • Erythromycin 40 mg/kg/day PO in divided doses for at least 14 days† |
Sexually Transmitted Infections
Attachment – STI Treatment Guidelines

Date Reviewed: May, 2015

Section: 5
Page 2 of 13

>1 month to <9 years

- **Azithromycin** 12-15 mg/kg (max. 1 g) PO in a single dose

  **Alternatives**
  - **Erythromycin** 40 mg/kg/day PO in divided doses (max. 500 mg qid for 7 days or 250 mg qid for 14 days) *†
  - **OR**
  - **Sulfamethoxazole** 75 mg/kg/day PO in divided doses (max. 1 g bid) for 10 days†

9-18 years

- **Preferred**
  - **Doxycycline** 5 mg/kg/day PO in divided doses (max. 100 mg bid) for 7 days
  - **OR**
  - **Azithromycin** 12-15 mg/kg (max. 1 g) PO in a single dose if poor compliance is expected

  **Alternatives**
  - **Erythromycin** 40 mg/kg/day PO in divided doses (max. 500 mg qid for 7 days or 250 mg qid for 14 days) *†

Source: Canadian Guidelines on Sexually Transmitted Infections 2010.

*Erythromycin dosages refer to the use of erythromycin base. Equivalent dosages of other formulations may be substituted (with the exception of the estolate formulation being contraindicated in pregnancy).
†If erythromycin or sulfamethoxazole has been used for treatment, repeat testing after completion of therapy is advisable.

**Notes:**
- Neonates born to infected mothers must be tested for *C. trachomatis*. Neonates should be treated if their test results are positive. They should be closely monitored for signs of chlamydial infection (e.g., conjunctivitis, pneumonitis). Prophylaxis is not recommended unless follow-up cannot be guaranteed.
- Test of cure should be performed 4 weeks after the completion of treatment in prepubertal children.

**Additional Information Regarding Treatment**
- Topical therapy alone for conjunctivitis is NOT adequate and is unnecessary when systemic treatment is used.
The use of erythromycin in infants under 6 weeks of age has been associated with infantile hypertrophic pyloric stenosis (IHPS). The risk of IHPS with other macrolides (e.g., azithromycin, clarithromycin) is unknown. The risks and benefits of using erythromycin in such infants must be explained to parents. When erythromycin is used in such infants, it is important to monitor for signs and symptoms of IHPS. IHPS following erythromycin use should be reported to the Canadian Adverse Drug Reaction Monitoring Program at 1-866-234-2345.

The need to treat infants under 6 weeks for C. trachomatis can be avoided by screening pregnant women and treating before delivery.

Doxycycline is contraindicated in children less than 9 years of age.

Quinolones have been associated with articular damage in young animals. Such joint changes have not been clearly attributable to quinolone use in children. Its safety in children has not been established. Quinolones should not be used in prepubertal patients. Experience in pubertal patients under 18 years of age is limited.

Table 3. Chlamydia. Pregnant women and nursing mothers: Urethral, endocervical, rectal infection

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>500 mg PO tid for 7 days*</td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>2 g/day PO in divided doses for 7 days*†</td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>1 g/day PO in divided doses for 14 days*‡</td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td>Azithromycin</td>
<td>1 g PO in a single dose, if poor compliance is expected†</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections 2010.

*If erythromycin or amoxicillin has been used for treatment in nursing mothers, test of cure should be performed 4 weeks after the completion of treatment.
†Erythromycin dosages refer to the use of erythromycin base. Equivalent dosages of other formulations may be substituted (with the exception of the estolate formulation being contraindicated in pregnancy). Gastrointestinal side effects are more severe with erythromycin than amoxicillin.
‡If vomiting occurs more than 1 hour post-administration, a repeat dose is not required.

Notes:

- Test of cure should be performed 4 weeks after the completion of treatment in all pregnant women.
Gonorrhea

Antimicrobial resistant gonorrhea (AMR-GC) continues to be of concern in Canada and globally. In order to determine the most appropriate treatment individuals must be assessed for the following specific risk factors and sexual behaviours prior to being treated for gonorrhea:

- history of MSM (men who have sex with men),
- history of oral sex,
- history of anal sex,
- sex with a person outside of Saskatchewan or Canada.

Treatment with the following MUST be given if the patient answers yes to any of the identified risk factors OR if the assessment is not completed:

- Ceftriaxone 250 mg IM (lidocaine 1% is the preferred diluent); AND
- Azithromycin 1 gram orally.

The following treatment is only appropriate when the above risk factors have been ruled out:

- Cefixime 800 mg orally; AND
- Azithromycin 1 gram orally.

In the absence of a contraindication, the following tables outline treatment options that should be considered in conjunction with the above guidelines.

**Anogenital and Pharyngeal Infections**

**Table 1. Gonorrhea. Recommended treatment of uncomplicated anogenital and pharyngeal infection in adults and youth 9 years of age and older (for MSM, see Table 2)**

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urethral, endocervical, vaginal, rectal</strong></td>
<td><strong>Spectinomycin 2 g IM in a single dose</strong>&lt;sup&gt;¥&lt;/sup&gt; (available only through Special Access Program [SAP]) PLUS</td>
</tr>
<tr>
<td>• Ceftriaxone 250 mg IM in a single dose</td>
<td>• Azithromycin 1 g PO in a single dose</td>
</tr>
<tr>
<td>PLUS</td>
<td>PLUS</td>
</tr>
<tr>
<td>• Azithromycin 1 g PO in a single dose</td>
<td>• Azithromycin 2 g PO in a single dose</td>
</tr>
<tr>
<td>OR</td>
<td>OR</td>
</tr>
<tr>
<td>• Cefixime 800 mg PO in a single dose</td>
<td>• Azithromycin 2 g PO in a single dose</td>
</tr>
<tr>
<td>PLUS</td>
<td>PLUS</td>
</tr>
<tr>
<td>• Azithromycin 1 g PO in a single dose</td>
<td>• Azithromycin 1 g PO in a single dose</td>
</tr>
</tbody>
</table>

<sup>¥</sup> Available only through Special Access Program (SAP)

<sup>§</sup> Azithromycin 2 g orally is preferred over the 1 g dose for treating gonorrhea.
**Sexually Transmitted Infections**
**Attachment – STI Treatment Guidelines**

Date Reviewed: May, 2015
Section: 5
Page 5 of 13

---

### Pharyngeal

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ceftriaxone 250 mg IM in a single dose† PLUS</td>
<td>• Cefixime 800 mg PO in a single dose§ PLUS</td>
</tr>
<tr>
<td>• Azithromycin 1 g PO in a single dose‡</td>
<td>• Azithromycin 1 g PO in a single dose†</td>
</tr>
<tr>
<td>OR</td>
<td>• Azithromycin 2 g PO in a single dose◊</td>
</tr>
</tbody>
</table>

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

* Cefixime and ceftriaxone should not be given to persons with a cephalosporin allergy or a history of immediate and/or anaphylactic reactions to penicillins.
† The preferred diluent for ceftriaxone is 1% lidocaine without epinephrine (0.9 mL/250 mg, 0.45 mL/125 mg) to reduce discomfort.
‡ Alternate combination therapy: Azithromycin 1 g PO is preferred over the alternative of doxycycline 100 mg PO bid X 7 days, due to significant rates of tetracycline-resistant gonorrhea and concerns regarding compliance with a 7-day treatment regimen. **Doxycycline is contraindicated in pregnant and breastfeeding women.**
§ There is scientific evidence that cefixime 800 mg is safe and effective in treating gonococcal infections. Pharmacodynamic studies have shown that 800 mg of cefixime compared to 400 mg, increases the period when the free drug concentration exceeds the MIC. Therefore, a dosage of 800 mg may be more effective than the previously recommended 400 mg at reducing the risk of gonococcal treatment failure in settings of reduced cephalosporin susceptibility.
◊ Not effective for pharyngeal infection. Test of cure is recommended.
¶ For anogenital infection, azithromycin 2 g PO in a single dose should only be considered as an alternate treatment option if there is a history of severe allergy to cephalosporins. It is important to recognize the risk of treatment failure when using azithromycin monotherapy for the treatment of gonorrhea in settings of emerging azithromycin resistance. There are also significant gastrointestinal side effects associated with high dose azithromycin.
◊ For pharyngeal infection, in case of severe allergy to cephalosporins, azithromycin 2 g PO may be considered as an alternate treatment option.

**Table 2. Gonorrhea. Treatment of Uncomplicated anogenital and pharyngeal infection in MSM**

<table>
<thead>
<tr>
<th>Urethral, rectal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred</td>
</tr>
<tr>
<td>• Ceftriaxone 250 mg IM in a single dose† PLUS</td>
</tr>
<tr>
<td>• Azithromycin 1 g PO in a single dose‡</td>
</tr>
</tbody>
</table>

---

Communicable Disease Control Manual
**Sexually Transmitted Infections**  
**Attachment – STI Treatment Guidelines**

Date Reviewed: May, 2015  
Section: 5  
Page 6 of 13

### Pharyngeal

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Alternatives</th>
</tr>
</thead>
</table>
| - Ceftriaxone 250 mg IM in a single dose<sup>①<sup>†</sup>  
PLUS  
- Azithromycin 1 g PO in a single dose<sup>‡</sup> | - Cefixime 800 mg PO in a single dose<sup>§</sup>  
PLUS  
- Azithromycin 1 g PO in a single dose<sup>¶</sup> |

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

* Cefixime and ceftriaxone should not be given to persons with a cephalosporin allergy or a history of immediate and/or anaphylactic reactions to penicillins.

† The preferred diluent for ceftriaxone is 1% lidocaine without epinephrine (0.9 mL/250 mg, 0.45 mL/125 mg) to reduce discomfort.

‡ **Alternate combination therapy:** Azithromycin 1 g PO is preferred over the alternative of doxycycline 100 mg PO bid X 7 days, due to significant rates of tetracycline-resistant gonorrhea and concerns regarding compliance with a 7-day treatment regimen. **Doxycycline is contraindicated in pregnant and breastfeeding women.**

§ There is scientific evidence that cefixime 800 mg is safe and effective in treating gonococcal infections. Pharmacodynamic studies have shown that 800 mg of cefixime compared to 400 mg, increases the period when the free drug concentration exceeds the MIC. Therefore, a dosage of 800 mg may be more effective than the previously recommended 400 mg at reducing the risk of gonococcal treatment failure in settings of reduced cephalosporin susceptibility.

¥ Not effective for pharyngeal infection. Test of cure is recommended.

¹ For anogenital infection, azithromycin 2 g PO in a single dose should only be considered as an alternate treatment option if there is a history of severe allergy to cephalosporins. It is important to recognize the risk of treatment failure when using azithromycin monotherapy for the treatment of gonorrhea in settings of emerging azithromycin resistance. There are also significant gastrointestinal side effects associated with high dose azithromycin.

² For pharyngeal infection, in case of severe allergy to cephalosporins, azithromycin 2 g PO may be considered as an alternate treatment option.
Table 3. Gonorrhea. Recommended treatment of Uncomplicated anogenital and pharyngeal infection in children <9 years of age.

<table>
<thead>
<tr>
<th>Urethral, vaginal, rectal</th>
<th>Pharyngeal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred</strong></td>
<td><strong>Alternatives</strong></td>
</tr>
<tr>
<td>- Ceftriaxone 50mg/kg IM up to 250 mg in a single dose*†</td>
<td>- Spectinomycin 40 mg/kg IM in a single dose (maximum dose of 2 g)‡ (available only through Special Access Program [SAP]) PLUS</td>
</tr>
<tr>
<td>- Azithromycin 20mg/kg (maximum dose of 1 g) PO in a single dose</td>
<td>- Azithromycin 20mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
<tr>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td>- Cefixime 8 mg/kg PO BID X 2 doses (maximum 400 mg/dose) PLUS</td>
<td>- Cefixime 8 mg/kg PO BID X 2 doses (maximum 400 mg/dose) PLUS</td>
</tr>
<tr>
<td>- Azithromycin 20mg/kg (maximum dose of 1 g) PO in a single dose</td>
<td>- Azithromycin 20mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
</tbody>
</table>

**Important notes related to neonates (birth to one month of age):**
- In neonates the recommended dosage for ceftriaxone is 25-50 g/kg (maximum of 125 mg).
- **Routine combination therapy with a macrolide is not recommended** due to the association with pyloric stenosis. Testing should be done for Chlamydia and if results are positive, treatment should be provided as per the Chlamydia chapter.

*Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.*

* Cefixime and ceftriaxone should not be given to persons with a cephalosporin allergy or a history of immediate and/or anaphylactic reactions to penicillins.
† The preferred diluent for ceftriaxone is 1% lidocaine without epinephrine (0.9 mL/250 mg, 0.45 mL/125 mg) to reduce discomfort.
‡ Not effective for pharyngeal infection. Test of cure is recommended.
Table 4. Gonorrhea. Recommended treatment of gonococcal ophthalmia and disseminated infections in adults and youth 9 years of age and older.

<table>
<thead>
<tr>
<th>Infections</th>
<th>Preferred treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>Ceftriaxone 2 g IV/IM daily for 7 days <strong>PLUS</strong> Azithromycin 1 g PO in a single dose</td>
</tr>
<tr>
<td>Meningitis</td>
<td>Ceftriaxone 2 g IV/IM daily for 10-14 days <strong>PLUS</strong> Azithromycin 1 g PO in a single dose</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>Ceftriaxone 2 g IV/IM daily for 28 days <strong>PLUS</strong> Azithromycin 1 g PO in a single dose</td>
</tr>
<tr>
<td>Ophthalmia</td>
<td>Ceftriaxone 2 g IV/IM in a single dose <strong>PLUS</strong> Azithromycin 1 g PO in a single dose</td>
</tr>
</tbody>
</table>

NOTE: Hospitalization is indicated for meningitis and may also be indicated for other disseminated infections.

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

*This is the usual duration of therapy but all cases should be discussed with an infectious diseases expert.

Table 5. Gonorrhea. Recommended treatment of gonococcal ophthalmia and disseminated infections in children >1 month and < 9 years of age.

<table>
<thead>
<tr>
<th>Infections</th>
<th>Preferred treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>Ceftriaxone 50 mg/kg IV/IM daily for 7 days (maximum dose of 1 g/day) <strong>PLUS</strong> Azithromycin 20 mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
<tr>
<td>Meningitis</td>
<td>Ceftriaxone 50 mg/kg IV/IM q 12 h for 10-14 days (maximum dose of 1 g/dose and 2 g/day) <strong>PLUS</strong> Azithromycin 20 mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>Ceftriaxone 50 mg/kg IV/IM q 12 h for 28 days (maximum dose of 1 g/dose and 2 g/day) <strong>PLUS</strong> Azithromycin 20 mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
<tr>
<td>Ophthalmia beyond neonatal period</td>
<td>Ceftriaxone 50 mg/kg IV/IM in a single dose (maximum dose of 2 g) <strong>PLUS</strong> Azithromycin 20 mg/kg (maximum dose of 1 g) PO in a single dose</td>
</tr>
</tbody>
</table>

NOTE: Hospitalization is indicated for meningitis and may also be indicated for other disseminated infections.

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

*This is the usual duration of therapy but all cases should be discussed with an infectious diseases expert.
Sexually Transmitted Infections
Attachment – STI Treatment Guidelines

Date Reviewed: May, 2015
Section: 5
Page 9 of 13

Gonorrhea and Neonates:
Neonates born to infected untreated mothers must be tested and treatment be initiated without waiting for test results.
Culture conjunctivae prior to administering antibiotics. If the infant is unwell in any way, also culture blood and cerebrospinal fluid to rule out disseminated infection.

Table 6. Gonorrhea. Ophthalmia neonatorum

<table>
<thead>
<tr>
<th>Preferred treatment:</th>
<th>Ceftriaxone 25-50 mg/kg IM in a single dose, maximum dose of 125mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important notes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Irrigate eyes immediately with sterile normal saline and at least hourly as long as necessary to eliminate discharge.</td>
</tr>
<tr>
<td></td>
<td>• Prophylactic treatment for possible chlamydial co-infection is not recommended unless follow-up cannot be assured. Testing should be done for chlamydia and if results are positive, treatment should be provided as per Chlamydia section.</td>
</tr>
<tr>
<td></td>
<td>• Hospitalization and consultation with an expert in infectious diseases should be initiated as soon as possible.</td>
</tr>
<tr>
<td></td>
<td>• Appropriate infection prevention and control precautions are necessary for all cases until 24 hours of effective therapy completed.</td>
</tr>
</tbody>
</table>

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

Table 7. Gonorrhea. Neonates born to women infected with gonorrhea

<table>
<thead>
<tr>
<th>Preferred treatment:</th>
<th>Ceftriaxone 25-50 mg/kg IM in a single dose, maximum dose of 125mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important notes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prophylactic treatment for possible chlamydial co-infection is not recommended unless follow-up cannot be assured. Testing should be done for Chlamydia and if results are positive, treatment should be provided as per Chlamydia section.</td>
</tr>
</tbody>
</table>

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

Table 8. Gonorrhea. Neonates with disseminated gonococcal arthritis, meningitis or endocarditis.

<table>
<thead>
<tr>
<th>Preferred treatment:</th>
<th>Cefotaxime 50 mg/kg IV/IM q6h for 10-14 days*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important notes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hospitalization and consultation with an expert in infectious diseases should be initiated as soon as possible.</td>
</tr>
<tr>
<td></td>
<td>• Prophylactic treatment for possible chlamydial co-infection is not recommended unless follow-up cannot be assured. Testing should be done for chlamydia and if results are positive, treatment should be provided as per Chlamydia section.</td>
</tr>
</tbody>
</table>

Source: Adapted from Public Health Agency of Canada, Gonococcal Infections Revised July 2013.

*This is the usual duration of therapy but all cases should be discussed with an infectious diseases expert.
Lymphogranuloma Venereum (LGV)

- In the absence of a contraindication, the following treatment options are recommended:

<table>
<thead>
<tr>
<th>Table 1. LGV. Treatment of lymphogranuloma venereum</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Line</strong></td>
</tr>
<tr>
<td>• Doxycycline 100 mg PO bid for 21 days</td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
</tr>
<tr>
<td>• Erythromycin 500 mg PO qid for 21 days*</td>
</tr>
<tr>
<td><strong>Possible</strong></td>
</tr>
<tr>
<td>• Azithromycin 1 g PO once weekly for 3 weeks†</td>
</tr>
</tbody>
</table>

Source: Canadian Guidelines on Sexually Transmitted Infections 2010.

*Erythromycin dosage refers to the use of erythromycin base. Equivalent dosages of other formulations may be substituted (with the exception of the estolate formulation, which is contraindicated in pregnancy); erythromycin (NOT the estolate formulation) should be used in pregnancy.

†While some experts believe azithromycin to be effective in the treatment of LGV, clinical data are lacking.

- Clients should be followed until chlamydial tests are negative (test of cure) and the client has clinically recovered. Test of cure should be performed at 4 weeks after the completion of effective treatment.
- Testing for chancroid and donovanosis (granuloma inguinale) should also be considered especially if there has been travel to regions where these infections are endemic.
- Aspiration of buboes may help symptomatically; however, incision/drainage or excision of nodes is not helpful and may delay healing.
- Suspected cases should be treated (with appropriate antibiotic regimen) empirically for LGV while awaiting test results.
Syphilis

- In the absence of a contraindication, the following treatment options are recommended:

<table>
<thead>
<tr>
<th>Stage</th>
<th>Preferred treatment</th>
<th>Alternative treatment for penicillin-allergic patients</th>
</tr>
</thead>
</table>
| All non-pregnant adults who are not co-infected with HIV               | Benzathine penicillin G 2.4 million units IM as a single dose<sup>1</sup> | • Doxycycline 100mg PO bid for 14 days
  • Alternative agents (only to be used in exceptional circumstances and should be discussed with the MHO)<sup>1</sup>
  • Ceftriaxone 1 g IV or IM daily for 10 days |
| Primary                                                               |                                                          |                                                        |
| Secondary                                                             |                                                          |                                                        |
| Early latent (<1 year duration)                                        |                                                          |                                                        |
| All non-pregnant adults                                               | Benzathine penicillin G 2.4 million units IM weekly for 3 doses | • Consider penicillin desensitization
  • Doxycycline 100mg PO bid for 28 days
  • Alternative agents (only to be used in exceptional circumstances and should be discussed with the MHO)<sup>1</sup>
  • Ceftriaxone 1 g IV or IM daily for 10 days |
| Late latent syphilis                                                  |                                                          |                                                        |
| Latent syphilis of unknown duration                                   |                                                          |                                                        |
| Cardiovascular syphilis and other tertiary syphilis not involving the central nervous system |                                                          |                                                        |
| All adults                                                            | Penicillin G 3-4 million units IV q4 h (16-24 million units/day) for 10-14 days | • Strongly consider penicillin desensitization followed by treatment with penicillin
  • Ceftriaxone 2 g IV/IM qd x 10-14 days |
| Neurosyphilis                                                         |                                                          |                                                        |
Sexually Transmitted Infections
Attachment – STI Treatment Guidelines

Date Reviewed: May, 2015

<table>
<thead>
<tr>
<th>Stage</th>
<th>Preferred treatment*</th>
<th>Alternative treatment for penicillin-allergic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiological treatment of sexual contacts in the preceding 90 days to primary, secondary and early latent syphilis§</td>
<td>Benzathine penicillin G 2.4 million units IM as a single dose.</td>
<td>See comment on Azithromycin¥</td>
</tr>
</tbody>
</table>

Source: Adapted from Canadian Guidelines on Sexually Transmitted Infections 2010.

*Reports from some jurisdictions have indicated inappropriate use of short-acting benzylpenicillin (Penicillin G) (IM) for the treatment of infectious syphilis rather than long-acting Benzathine penicillin G (Bicillin-LA). Practitioners, pharmacists and purchasing agents should be aware of the similar names of these two products to prevent and avoid inappropriate and inadequate treatment. Long-acting benzathine penicillin achieves detectable serum levels of penicillin for 2-4 weeks in non-pregnant adults and is required to adequately treat infectious syphilis; short acting penicillin agents are not adequate for achieving cure.

†Some experts recommend 3 weekly doses (total of 7.2 million units) of benzathine penicillin G in HIV infected individuals.

‡The efficacy data supporting the use of these agents is limited, and as such they should only be used in exceptional circumstances and when close patient follow-up is assured.

§If sexual contact is unreliable or unable to test, then epidemiological treatment should be strongly considered. Epidemiological treatment should be strongly considered in these individuals; even if more than 30 days after exposure (see Syphilis - Management of Contacts).

¥Azithromycin In light of recent reports of failure of azithromycin for the treatment of early syphilis and the rapid development of azithromycin resistance in T. pallidum, this agent should not be routinely used as a treatment option for early or incubating syphilis unless adequate and close follow up can be ensured, and only in jurisdictions where little to no azithromycin genotypic resistance in T. pallidum has been demonstrated. It should be noted, however, that at the present time, very limited Canadian data on the prevalence of Azithromycin resistance in T. pallidum is available, with 1 of 47 specimens between 2000-2003 as compared with 4 of 9 specimens from MSM in 2004-2005 collected in Vancouver demonstrating resistance. A recent analysis of specimens from Alberta showed that 4 of 14 syphilis cases between February 2007 and January 2008 were azithromycin resistant; all cases were in MSM except for one neonate with congenital syphilis whose father acquired syphilis outside of Canada.
### Table 2. Syphilis. Treatment: Pregnant women

<table>
<thead>
<tr>
<th>Stage</th>
<th>Preferred treatment*</th>
<th>Alternative treatment for penicillin-allergic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnant women</strong></td>
<td>Benzathine penicillin G 2.4 million units IM weekly for 1-2 doses†‡</td>
<td>• There is no satisfactory alternative to penicillin for the treatment of syphilis in pregnancy; insufficient data exist to recommend ceftriaxone in pregnancy. • Strongly consider penicillin desensitization followed by treatment with penicillin</td>
</tr>
<tr>
<td>• Primary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Secondary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Early latent (&lt;1 year duration)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pregnant women</strong></td>
<td>Benzathine penicillin G 2.4 million units IM weekly for 3 doses</td>
<td></td>
</tr>
<tr>
<td>• Late latent syphilis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Latent syphilis of unknown duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Cardiovascular syphilis and other tertiary syphilis not involving the central nervous system</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Reports from some jurisdictions have indicated inappropriate use of short-acting benzylpenicillin (Penicillin G) (IM) for the treatment of infectious syphilis rather than long-acting Benzathine penicillin G (Bicillin-LA). Practitioners, pharmacists and purchasing agents should be aware of the similar names of these two products to prevent and avoid inappropriate and inadequate treatment. Long-acting benzathine penicillin achieves detectable serum levels of penicillin for 2-4 weeks in non-pregnant adults and is required to adequately treat infectious syphilis; short acting penicillin agents are not adequate for achieving cure.

†Some experts recommend 3 weekly doses (total of 7.2 million units) of benzathine penicillin G in HIV infected individuals.

‡Given the complexity of accurately staging early syphilis, some experts recommend that primary, secondary and early latent cases in pregnancy be treated with 2 doses of benzathine penicillin G 2.4 million units 1 week apart; the efficacy of this regimen in preventing fetal syphilis is not known.